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suppression of premature cleavage and polyadenylation. The latter, termed telescripting, is the critical process
that allows for the creation of full-length pre-mRNA. Reducing the level of available U1 in cells relative to premRNA, either through global transcription up-regulation or functional U1 inhibition, causes widespread
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occurred through intron expansion as a result of telescripting. By conducting a series of high-throughput
sequencing experiments for both chromatin immunoprecipitation (ChIPseq) and RNA (RNAseq), I
demonstrated that PCPA is co-transcriptional and that it is an evolutionarily conserved transcription
regulation mechanism. I have shown that U1 inhibition caused PCPA selectively in large genes (median 39 kb
in human), which were enriched for developmental and differentiation functions, while small genes were
enriched for acute cell survival and stress response function are up-regulated under the same conditions.
Importantly, I proved that PCPA susceptibility is evolutionarily conserved and has been a major driving factor
in vertebrate intron size expansion. I demonstrated that this gene size-function polarization allows for large
genes to sacrifice transcription during cell stress and activation, supplying small genes necessary for cell
survival with RNA processing proteins that boost their mRNA productivity. Lastly, I have shown that minor
U1 inhibition caused general and previously unannotated multi-exon skipping events that can sometimes
occur between two, adjacent and same-stranded genes as a part of read through transcription including in
disease relevant genes. These results highlight the importance of U1, not only as a mechanism of transcription
regulation in all metazoans, but also as a primary contributor to the evolution of gene and genome structure.
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ABSTRACT
U1 SNRNP TELESCRIPTING: A TRANSCRIPTIONAL REGULATION MECHANISM
THAT HAS DRIVEN INTRON SIZE EXPANSION ACROSS EVOLUTION
Christopher Conrad Venters
Gideon Dreyfuss
U1 snRNP (U1) functions in controlling transcription through both the splicing of introns
and the suppression of premature cleavage and polyadenylation. The latter, termed
telescripting, is the critical process that allows for the creation of full-length pre-mRNA.
Reducing the level of available U1 in cells relative to pre-mRNA, either through global
transcription up-regulation or functional U1 inhibition, causes widespread premature
cleavage and polyadenylation (PCPA) from cryptic polyadenylation signals in introns.
Through the development of novel analytical programs for large sequencing datasets, I
identified the gene features that increase sensitivity to U1 inhibition and examined the
size-function polarization of genomes that has occurred through intron expansion as a
result of telescripting. By conducting a series of high-throughput sequencing experiments
for both chromatin immunoprecipitation (ChIPseq) and RNA (RNAseq), I demonstrated
that PCPA is co-transcriptional and that it is an evolutionarily conserved transcription
regulation mechanism. I have shown that U1 inhibition caused PCPA selectively in large
genes (median 39 kb in human), which were enriched for developmental and
differentiation functions, while small genes were enriched for acute cell survival and stress
response function are up-regulated under the same conditions. Importantly, I proved that
PCPA susceptibility is evolutionarily conserved and has been a major driving factor in
vertebrate intron size expansion. I demonstrated that this gene size-function polarization
allows for large genes to sacrifice transcription during cell stress and activation, supplying
small genes necessary for cell survival with RNA processing proteins that boost their
vi

mRNA productivity. Lastly, I have shown that minor U1 inhibition caused general and
previously unannotated multi-exon skipping events that can sometimes occur between
two, adjacent and same-stranded genes as a part of read through transcription including
in disease relevant genes. These results highlight the importance of U1, not only as a
mechanism of transcription regulation in all metazoans, but also as a primary contributor
to the evolution of gene and genome structure.
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CHAPTER 1: INTRODUCTION
RNA Transcription
The cellular function most crucial to life is the conversion of genetic information into
molecular machinery. Aptly described as the central dogma of molecular biology,
permanently stored sequence information, in the form of deoxyribonucleic acid (DNA), is
transformed into functional cellular machinery, mainly in the form of protein. At the heart
of this transfer is a molecule called ribonucleic acid (RNA), which is generated from
copying the genetic information stored in DNA through a process known as transcription.
The creation of protein coding messenger RNA (mRNA) from transcriptional units, called
genes, is carried out by a large, 12-subunit complex called RNA polymerase II (pol II)
(Cramer, Bushnell, and Kornberg 2001; Cramer et al. 2008). There are three definitive
stages to transcription: initiation, where a start site is selected, the DNA is unwound, and
pol II forms the beginning of the RNA strand; productive elongation of RNA as pol II moves
through the gene from 5’ to 3’; and finally, termination as pol II is released from the DNA
(Figure 1.1) (Holstege, Fiedler, and Timmers 1997).
The main subunit of pol II, Rbp1, has a C-terminal domain (CTD) that is unique to pol II
and is critical for regulating the various stages of transcription through phosphorylation of
various peptide residues (Shilatifard, Conaway, and Conaway 2003; Bowman and Kelly
2014). This CTD is made up of multiple heptad repeats, the consensus sequence being
Tyr1–Ser2–Pro3–Thr4–Ser5–Pro6–Ser7. Near to the transcription start site (TSS), Ser5
is heavily phosphorylated (Ser5p), but this is slowly replaced by Ser2p over the length of
the gene during elongation (Komarnitsky, Cho, and Buratowski 2000; Mayer et al. 2010;
Odawara et al. 2011). Ser2p addition is also known to help the polymerase overcome
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promoter proximal pausing (PPP), a vital transcription checkpoint. These different
phosphorylation states help the recruitment of proteins to the CTD that are involved in the
various stages of transcription, such as export factors or RNA processing factors (Egloff
and Murphy 2008; Heidemann et al. 2013). Much research has been done on the kinetics
of transcription, as pol II’s variable transcription speed and newly discovered
transcriptional checkpoints have been shown to be important regulators in termination site
usage and proper co-transcriptional processing of RNA (Darzacq et al. 2007; Wada et al.
2009; David et al. 2011; Jonkers, Kwak, and Lis 2014; Yang et al. 2016).
RNA Splicing and Its Machinery
During the early evolutionary stages of eukaryotes, and still found today in prokaryotes,
transcription was a one-to-one process where the entirety of a gene’s sequence
information is transcribed into utilized RNA. This information will, in turn, be converted by
the ribosome into a final peptide strand in a process called translation. More recent
evolutionary changes to transcription and, more importantly, RNA post-processing, has
allowed for selection of specific sequences to include in the final mRNA from the initially
produced RNA strand, pre-mRNA. The first iteration of sequence selection simply involved
pieces that were either removed, dubbed introns, or kept as coding sequences, dubbed
exons (Chorev and Carmel 2012). The mechanism of removing these intronic pieces of
RNA and subsequent ligation of exons to form the final, contiguous mRNA is called
splicing.
Modern eukaryotes take advantage of this intron-exon mosaicking for a variety of
outcomes, for example to include regulatory sequences or functional RNAs mid-gene,
while ultimately not affecting the translated protein product (Chorev and Carmel 2012).
Additionally, more complex eukaryotes can choose to include or exclude exons to
2

generate distinct yet related mRNAs and proteins from a common gene; these exons are
known most broadly as alternative exons (Figure 1.2). This is commonly seen with variants
of a single gene, called isoforms, that are functionally similar and yet specific to either one
tissue or cell type within a complex organism or are necessary only during certain stages
of development (E. T. Wang et al. 2008; Baralle and Giudice 2017; Iñiguez and Hernández
2017). The modularity allowed by alternative splicing thus decreases the number of
individual genes required to produce the increasingly diverse set of proteins needed for
organismal function in higher eukaryotes. As such, over the course of evolution, alternative
splicing of transcripts has allowed for an increasingly diverse proteome.
Only after splicing and other processing steps, i.e. 5’ end capping and 3’ polyadenylation,
can the mature mRNA be translated into protein by the ribosome. As this is such a critical
process, it should be no surprise that splicing is carried out by a multisubunit, megadalton
complex called the spliceosome. This molecular machine is comprised of dozens of
proteins and functional RNAs, at the core of which are the U-type small nuclear
ribonucleoproteins (snRNPs). These snRNPs were first discovered in the 1960’s (Hodnett
and Busch 1968; Weinberg and Penman 1968), but, without a physiological foundation in
which to place them, it took until 1979 before snRNPs were recognized to be involved in
splicing. This discovery was that one family member, U1 snRNP (U1), formed an
RNA:RNA base-pair with the 5’ splice site (5’ss) of an intron, which is the critical first step
in the splicing reaction (Lerner and Steitz 1979; Lerner et al. 1980; Mount et al. 1983;
Padgett et al. 1983). The major spliceosome, responsible for processing nearly all introns
in eukaryotes, is comprised of U1, U2, U4, U6, while U11, U12, U4atac, and U6atac make
up the minor version of this complex seen only in multicellular eukaryotes, with U5 being
the only snRNP shared between the two (Hall and Padgett 1994; Patel and Steitz 2003;
Wahl, Will, and Lührmann 2009).
3

The splicing reaction, which is often co-transcriptional, involves many steps of snRNP
engagement, rearrangement, and departure (Figure 1.3) (Wahl, Will, and Lührmann 2009;
Will and Lührmann 2011). Simply, it begins with U1 snRNA’s 5’ end recognizing and
binding to the 5’ss in order to define the upstream exon, thereby forming the E Complex.
U2, aided by the auxiliary splicing factors U2AFs and SF1, then identifies and binds to the
branch point adenosine at the 3’ end of the intron near the 3’ splice site (3’ss). The prespliceosomal A Complex is formed by recruitment of additional proteins and the
association of U1 and U2 through Prp5 and Sub2. The catalytic component of the
spliceosome, the U4/U6.U5 tri-snRNP, is then recruited to form the B Complex as U6
displaces U1 from the intron. The subsequent release of U4 then allows for the C Complex
to catalyze the transesterification reaction from the branch site adenosine onto the 5’ss,
cleaving the 5’ exon junction. A second transesterification ligates the 5’ exon onto the 3’
exon, resulting in the release of an intron lariat bound to U2, U5, and U6. The snRNPs are
then recycled for further rounds of splicing.
The snRNPs themselves are made up of a uridine rich small nuclear RNA (snRNA),
ranging in size from 100-300 nucleotides (nt), and a common heptameric ring made of Sm
or related Lsm proteins (Sm/Lsm core) (Figure 1.4) (Guthrie and Patterson 1988). U6 is
unique in that it is the only snRNP to utilize Lsm proteins that recognize its Lsm site (AU5)
rather than the more common Sm site and proteins. Each snRNP also possesses many
accessory proteins associated with specific proteins to aid in their function (Krämer et al.
1995; C. Wang et al. 1998; Pomeranz Krummel et al. 2009). The most well characterized
of these accessory proteins are on U1 snRNA, where stem-loop 1 is bound by U1-70K
which helps recruit it to the SMN complex (Battle et al. 2006; Lau, Bachorik, and Dreyfuss
2009; So et al. 2016). The remaining two U1 specific proteins may join at any time after
this with U1A binding to stem-loop 2, while U1C interacts at the stem near the 3’ and 5’
4

snRNA arms and aids in the critical RNA:RNA base pairing in splicing (Du and Rosbash
2002; Pomeranz Krummel et al. 2009).
Prior to assembly, the Sm proteins congregate into two heterodimers, SmB/D3 and
SmD1/D2, and a heterotrimer of SmF/E/G. Experiments in vitro showed that they are able
to spontaneously assemble into an Sm core around most uracil-rich RNA (Pellizzoni et al.
2002). Given that this protein ring is held tightly together and stable when bound to RNA,
even under high salt and detergent conditions, it would be highly deleterious if allowed to
run free within a cell as they could form on an off-target RNA and inhibit its canonical
function (Yong, Wan, and Dreyfuss 2004). As such, the assembly of the Sm core around
the snRNA’s Sm site (AU2-4G/UUG) is highly regulated by the survival of motor neurons
(SMN) complex (U. Fischer, Liu, and Dreyfuss 1997; Liu et al. 1997; Meister et al. 2001;
Yong et al. 2004; Cauchi 2010; Utz Fischer, Englbrecht, and Chari 2011; So et al. 2016).
The SMN complex is made up of the SMN protein, associated Gemin proteins (2-8), and
unrip. Studies into SMN deficiencies, which are known to cause the genetic wasting
condition spinal muscular atrophy (SMA), have intriguingly shown a tissue-specific altered
snRNP repertoire, rather than uniform decreases across the entire family (Gabanella et
al. 2007; Z. Zhang et al. 2008; Workman et al. 2009). This fact, combined with the
knowledge that snRNP abundance in cells is highly variable despite their 1:1 stoichiometry
in the splicing reaction (Baserga and Steitz 1993), led us to target each snRNP individually
for experimental knockdown in order to assess the transcriptomic changes in tissue
cultures.
Functional snRNP Knockdown and U1 Telescripting
We directly examined the individual activity of each of these snRNPs through functional
knockdown experiments in HeLa cells. We relied on the transfection of antisense
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morpholino oligonucleotides (AMOs) to alter the functional snRNP repertoire for our
studies rather than small-interfering RNAs (siRNAs) because the former are easier to
control, do not destroy the target RNP, and act much more quickly (4-8 hours versus 2448 hours, respectively (Kaida et al. 2010)). These 25-mer oligos were targeted to a specific
sequence of the snRNA both to block their binding to pre-mRNA, and because U1 and
U12 AMOs had been shown to inhibit splicing in a few tested introns (Figure 1.4) (Matter
and König 2005). U1 AMO, specifically, was of interest due to U1’s importance in the first
steps of splicing and its high abundance, at roughly 1,000,000 copies in cells; this is
several fold more than U4 and U6.
Dose response of the AMO functional knockdowns was tested both with fluorescent in situ
hybridization and RNase H protection assays (Kaida et al. 2010). The former utilized
fluorescent LNA probes complementary to U1’s 5’ snRNA end, while the latter utilizes
RNase H and a DNA probe, similar to the LNA probe, so that bound snRNA gets cleaved
and degraded. A decrease in snRNA cleavage was seen after U1 AMO treatments, as it
inhibited DNA:RNA base-pairing and RNAseq H cleavage, and allowed us to determine
optimal doses for near complete functional inhibition of U1. Initial results with in vitro target
introns also showed decreased splicing, further confirming these results.
Global testing of these U1 and U2 AMO treatments were initially performed using high
density genomic tiling arrays (Figure 1.5) (Kaida et al. 2010). Results from these
experiments were puzzling, as RNA reads in many genes were concentrated towards the
5’ end, with signal tapering out almost to nothing within a few kilobases (kb) of the
transcription start site (TSS) in introns. It should be stated that, despite these novel results,
intron retention was apparent in many cases upstream of the point at which the read signal
terminated in these introns, confirming U1’s role in splicing. In comparison, however, U2
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AMO and treatment with spliceostatin A (SSA), which inhibits splicing by suppressing the
activity of the critical U2 protein SF3B1, showed global increases in intron retention as
seen by increases in splice site and intronic reads (Kaida et al. 2007; Kotake et al. 2007).
There was no detectable 5’ aggregation of signal with U2 AMO or SSA, indicating that the
phenomenon was specific to U1 base-pairing inhibition.
There were multiple possible mechanistic explanations behind the production of these
RNAs near the 5’ end of genes. For example, the pol II could be paused yet still engaged,
similar to those found near the promoter; alternatively, it is possible that full-length mRNAs
are actively being degraded from their 3’ end, leaving 5’ sequences; lastly, pol II
transcription could be terminating early within the gene. In order to further study this
observation, we turned to other techniques paired with our original AMO knockdown
treatments. We targeted a select number of these apparent 3’ termination sites with
primers to produce complementary DNA (cDNA) for both PCR amplification and
sequencing (Scotto-Lavino, Du, and Frohman 2006). This 3’ rapid amplification of cDNA
ends (3’-RACE) showed that the truncated transcripts were polyadenylated similar to the
canonical ends of genes (Kaida et al. 2010). In fact, these stretches of non-genomic
polyadenylation (poly(A)) were also found to have consensus polyadenylation signals
(PAS; AAUAAA or other variants; (N. J. Proudfoot and Brownlee 1976; Magana-Mora,
Kalkatawi, and Bajic 2017)) 20-60nt upstream. These are the signals typically utilized by
the cleavage and polyadenylation (CPA) machinery to terminate mRNA transcription at a
genes’ 3’ end (Shi and Manley 2015; Tian and Manley 2017). Utilizing a mutated and
inactivated PAS in reporter genes demonstrated that this premature CPA (PCPA) is
dependent on the upstream PAS similar to canonical 3’ gene ends. PCPA products were
still produced from nearby, downstream PAS after mutation, although not near to the
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inactivated site. Taken together, these results indicated that this phenomenon is not
hinged on a single PAS and is directional from 5’ to 3’, similar to transcription.
We more precisely identified these PCPA locations using a high throughput sequencing
strategy of differentially expressed transcripts (HIDE-seq) (Berg et al. 2012). This protocol
utilized subtractive hybridization (Diatchenko et al. 1996; Gurskaya et al. 1996) of cDNA
fragments from either control or U1 AMO treated poly(A) transcripts in order to eliminate
unchanged sequences (Figure 1.6). PCR amplification of the remaining pool results in a
sequencing library only enriched in differentially expressed portions of the genome. HIDEseq employed on human, mouse, and fruit fly cell lines showed that PCPA was a
conserved phenomenon due to U1 base-pairing inhibition across metazoans.
Furthermore, we found that PCPA typically occurred within 1kb from the first 5’ss.
Assuming that U1 bound to the 5’ss could also function to prevent PCPA, an activity we
termed telescripting, this would suggest that a single U1 snRNP could protect roughly 1kb
of transcription. This result was confirmed through mutation of several 5’ss, which resulted
in PCPA from a PAS ~1kb downstream. Furthermore, the use of a synthetic U1 snRNA,
complementary to the now mutated 5’ss, resulted in the restoration of telescripting and,
thus, downstream transcription.
There were cases with U1 AMO, however, where transcription extended for 10’s of kb
before premature termination (Berg et al. 2012). This was suggestive of a mechanism
where U1 may bind to a 5’ss for the purpose of splicing and could also suppress a nearby
PAS; however, downstream sites may be unprotected by U1. This would be problematic
in genes with introns larger than 1kb, a feature found very often in vertebrates, as introns
are replete with cryptic PASs. This suggests that U1 should be required for telescripting
not only at the 5’ss, but within almost all intronic sequences in genes. Supporting this
8

conclusion is the fact that U1’s base pairing is also known to be degenerate and influenced
by other RNA binding proteins (RBPs); in fact, recent studies have shown that U1 does in
fact bind throughout introns rather than only at the 5’ss (Engreitz et al. 2014). When
combined, these observations are indicative of a model where all PAS usage is under the
control of U1, and any PAS could potentially be recognized, and acted upon, by the CPA
machinery (Figure 1.7).
While these high levels of U1 AMO knockdowns inhibited ~95-99% of U1, we also used
HIDE-seq to examine the effect that significantly lower doses have on transcription
efficiency, reasoning that this would be more similar to physiological occurrences (Berg et
al. 2012). Blocking 15% of available U1 resulted in much more distal PCPA, best
characterized as 3’ untranslated region (3’UTR) shortening or alternative 3’ endprocessing. This phenomenon has been well characterized, as proximal PAS usage in
3’UTRs through alternative polyadenylation (APA) is associated with activated cell states
such as immune cell or neuron stimulation, cell proliferation, and cancer (Niibori et al.
2007; Flavell et al. 2008; Sandberg et al. 2008; Mayr and Bartel 2009; Lianoglou et al.
2013). Here, shortened 3’UTRs often result in increased protein translation as there are
many binding sites for regulatory factors, such as microRNAs (miRNAs), in the distal part
of these regions (Mayr 2017). The loss of these sites can result in changes in mRNA
stability, translation efficiency, and mRNA localization (Figure 1.8). There were also cases
where low U1 AMO doses induced alternative last exon usage, resulting in shortened, but
often annotated and functional, mRNA isoforms. A frequently cited example of this is in
the case of homer-1, a scaffolding protein that is necessary for synaptogenesis and in the
postsynaptic density (PSD) (Niibori et al. 2007). The long form, homer-1l, is constitutively
expressed and localized in the PSD, while neuronal stimulation results in an isoform switch
to the short version, homer-1s. Without its carboxyl-terminal portion of the protein, homer9

1s antagonizes homer-1l and can cause epilepsy through over-stimulation. Several low
U1 AMO concentrations mimicked the physiological isoform switching in homer-1 in a
dose-dependent manner (Berg et al. 2012).
Into the Modern Era
With both the decreasing costs and increasing data quality from high-through sequencing,
both for RNA (RNAseq) and target protein immunoprecipitation (various IPseq), we taken
advantage of this technology to thoroughly study U1’s role in telescripting. In order to more
specifically target active transcription after transfection, we also relied on metabolic RNA
labeling with 4-thiouridine (4sU). This labeling incorporates 4sU into elongating premRNA, allowing for isolation of nascent transcripts. Combining these two advancements
has drastically increased the resolution of transcriptomic changes, elucidating more of the
U1 telescripting story and mechanism. I have worked to create innovative analytical work
to address the novelty of the discovery of PCPA and availability of such extensive data,
as well as flesh out the mechanism of telescripting through critical U1 AMO based
experiments.
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Figure 1.1 RNA transcription by RNA polymerase II
A stepwise model of RNA transcription from pol II and the various CTD phosphorylation
states associated with each phase. The red line extending from the red pol II body shows
the CTD heptad repeat in amino acid code (Y = Tyrosine, S = Serine, P = Proline, T =
Threonine). The “P” inset in the blue circle represents the phosphoryl group used for
regulation of transcription. The black line and ball represent the nascent pre-mRNA and
5’ cap, respectively.
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Figure 1.2 Structure of pre-mRNA and possible mRNA splicing isoforms
Pre-mRNA, in the middle of the scheme, is comprised of introns (solid black line) and
exons (colored and numbered boxes). Exon to exon splicing is depicted by the dashed
black lines above and below the pre-mRNA, which creates the associated mRNA
products. Exons are differentiated to be included in both mRNA transcripts (green),
alternatively spliced (blue), or as cassette exons (red). Thinner green boxes depict UTR
regions. Transcription direction is indicated as 5’ to 3’.
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Figure 1.3 Pre-mRNA splicing mediated by the major spliceosome
A stepwise model of the canonical assembly and disassembly of the spliceosome during
the intron splicing process. Additions to the spliceosome are shown as black arrows, while
departures are shown as grey arrows. The snRNPs are depicted as colored ovals, exons
as colored boxes, and intron as the black line connecting exons. The splicing relevant
nucleotide sequences, are shown as colored letters in the intron; invariant dinucleotides
in blue and green and branch point adenosine in red. For simplicity, no accessory
spliceosomal proteins are shown. Figure adapted from Will and Lührmann (Will and
Lührmann 2011).
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Figure 1.4 snRNP structure and mechanism of action of AMO inhibition
Left, U1 snRNP, including the snRNA (black line), U1 specific proteins (colored circles)
and Sm core (green circles around the red Sm site), is shown bound to the 5’ splice site
by base-pairing interactions (vertical black lines). Right, U1 AMO, red line, binds to the 5’
sequence of U1 snRNA, inhibiting U1 from binding 5’ splice sites and other, similar
sequences in introns. Figure adapted from Venters et al. 2019 (Venters et al. 2019).
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Figure 1.5 Genomic tiling array identifies PCPA and splicing inhibition
RNA from control, U1 AMO transfected (8hr, 7.5 μM), or SSA treated (8hr, 100 ng/mL)
HeLa cells were analyzed using genomic tiling arrays. Signal intensity log fold change of
2

treated cells versus control cells is shown in light blue above the gene structure shown as
black lines for introns and black boxes for exons. Red arrows note the point of signal drop
after U1 AMO transfections indicative of PCPA. Genomic distances are shown as dashed
black lines. Figure adapted from Kaida et al. (Kaida et al. 2010).
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Figure 1.6 HIDE-seq enriches for transcriptome changes and PCPA location
(a) Enrichment of transcriptome changes from control transfected or U1 AMO transfected
cells is shown from subtractive hybridization of U1 minus control (red, U1-Ctrl) or control
minus U1 (green, Ctrl-U1) either above or below gene structures, respectively. Data is
from HeLa (Human), NIH-3T3 (Mouse), or S2 (Fruit Fly) cells. Black lines represent
introns, black boxes represent exons, and colored dashed lines represent spliced intron
signal. Black arrows indicate reads with non-genomic poly(A) tails. Full sequences of
HIDE-seq reads are shown below the genomic DNA from human, mouse, or fly. Genomic
distances are shown as dashed black lines. (b) Density graphs of reads with poly(A) tails
present after U1 AMO transfection in human, mouse, or fly cells relative to their distance
from the TSS are plotted. Figure adapted from Berg et al. (Berg et al. 2012).
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Figure 1.7 A proposed model of U1 telescripting
A cartoon model depicting the process of telescripting. Pol II CTD, green line, associates
early in transcription with cleavage and polyadenylation (CPA) factors, shown as colored
ovals. U1 snRNP, bound to 5’ splice sites or intronic U1 binding sites, prevents CPA
factors from activating cryptic polyadenylation signals and eliciting premature CPA
(PCPA). U1 can protect nascent transcripts from PCPA for distances of roughly 1kb.
Exons are shown as blue boxes, PAS as red boxes, and introns as black lines. Figure
adapted from Berg et al. (Berg et al. 2012).
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Figure 1.8 Mild U1 base pairing inhibition recapitulates mRNA isoform switching
and 3’UTR shortening seen in neuronal activation
(a) Rat PC12 neurons were treated for 3 hours with forskolin or forskolin/KCl, or separately
transfected with increasing doses of U1 AMO. RT-PCR results with primers for either the
short or long form of homer-1 show the shift from long to short isoform with U1 AMO or
forskolin. Gene structures are shown above, with inset highlighting the short (red) or long
(green) isoform structure and arrows for the primer locations. (b) HIDE-seq results from
HeLa cells for U1 AMO transfected versus control (red, U1-Ctrl) or vice versa (green, CtrlU1) in 3’UTRs. Black arrows indicate reads with non-genomic poly(A) tails. For gene
structure lines depict introns, boxes depict exons, and thinner boxes depict UTRs.
Genomic distances are shown as dashed black lines. Figure adapted from Berg et al.
(Berg et al. 2012).
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CHAPTER 2: METHODS
Experimental Methods
AMO Transfection
Cells are grown in full media, DMEM supplemented with 10% fetal bovine serum (FBS)
and 1% Penicillin and Streptomycin (P/S), until they are 70-80% confluent. If the cell line
is adherent, Danio rerio ZF4 or Mus musculus 3T3 cells, the media is removed and the
cells are washed with phosphate buffered saline (PBS) and 0.25% Trypsin-EDTA
(ThermoFisher) is used to detach them. Non-adherent cells, Drosophila melanogaster
Schneider 2 (S2), are spun down at 2,000g for 2 minutes at room temperature (RT), the
supernatant is removed and the pellet is washed with PBS. Cells are resuspended in
media with 10% FBS, then counted using a NucleoCounter (ChemoMetec). 1x106 cells
are used per reaction. AMO transfection of the desired concentration is carried out via
electroporation using either the Neon Transfection System (ThermoFisher) or the Amaxa
Nucleofector System (Lonza) using buffers and pulse programs optimized for each cell
line from the manufacturer. Once electroporated, the cells are immediately resuspended
in full media and allowed to grow for the desired experiment time.
4sU Labeling and Purification
30 minutes prior to harvesting cells, 4sU (Sigma) is added to a final concentration of
200μM. The media is then removed and TRIzol (ThermoFisher) is used to harvest and
homogenize cells as per the manufacturer’s instructions. Total RNA is extracted from the
TRIzol with chloroform and precipitated with ethanol.
RNA is biotinylated by shaking at 1,000 RPM for 1.5 hours at RT with 0.2mg/mL EZ-Link
HPDP-Biotin (ThermoFisher) in binding buffer (10mM Tris pH 7.5, 1mM EDTA) to a final
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concentration of 100ng/mL. Equal volume of chloroform:isoamyl alcohol (24:1) is added
and RNA is extracted using a silicone phase divider gel (polydimethylsiloxane and silicone
dioxide, Dow Corning). The biotinylated RNA is precipitated using isopropanol, then
resuspended in water and captured on Dynabeads MyOne Streptavidin C1 (Invitrogen) as
follows. A 100μL aliquot of beads is first prepared over three wash phases: three times
with 1mL of a first wash buffer (5mM Tris pH 7.5, 0.5mM EDTA, 1M NaCl), twice with 1mL
of a second buffer (0.1M NaOH, 0.05M NaCl), once with 1mL of a third buffer (0.1M NaCl),
and then resuspended in 100μL of 10mM Tris pH 7.5, 1mM EDTA, 2M NaCl. The RNA is
bound to the beads at equal volume over 15 minutes at RT, then separated from the
solution on a magnet. The beads are washed three times with 1mL of wash buffer (100mM
Tris pH 7.5, 10mM EDTA, 1M NaCl, 0.1% Tween20) at 65°C and then 3x again with the
same wash buffer at RT. The purified RNA is recovered from the beads with two elutions
of 100mM DTT and precipitated using ethanol. Final RNA concentration and quality is
tested on a Bioanalyzer (Agilent).
Ribosomal RNA (rRNA) Depletion
Depletion of rRNA is done using the Ribo-Zero rRNA Removal Kit (Illumina) following the
manufacturer’s instructions. For non-human, mouse, or rat samples, the rRNA level is
checked on a Bioanalyzer after one pass. If residual, unwanted rRNA remains, a second
run with the kit is required. Of note, the Ribo-Zero includes an upper limit to the input RNA
concentration. This, combined with the low concentrations of labeled RNA from the short
(30 minute) 4sU label, means that 4sU selection should be carried out first. Final RNA
concentration and quality is tested on a Bioanalyzer (Agilent).
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RNAseq Library Preparation
Strand-specific RNAseq sequencing libraries are created using the KAPA Stranded RNASeq Library Preparation Kit (Kapa Biosystems) per the manufacturer’s instructions. The
SeqCap Adapter Kit A is used (Roche). Final library concentration and quality is tested on
a Bioanalyzer (Agilent).
Pol II ChIPseq
Cells, grown as described above, are detached with Trypsin and washed with PBS; 1%
formaldehyde in PBS is then used to crosslink protein and DNA at RT for 15 minutes.
Excess formaldehyde is quenched using glycine to a final concentration of 125mM. The
cells are spun (2,000g for 5 minutes) and resuspended in lysis buffer (5mM HEPES K pH
7.9, 85mM KCl, 0.5% NP-40, cOmplete protease inhibitor from Roche). Nuclei are spun
at 3,900g for 5 minutes at 4°C and resuspended in nuclei lysis buffer (50mM Tris-HCl pH
8.0, 1mM EDTA pH 8.0, 1% SDS, cOmplete protease inhibitor from Roche). The
chromatin is sonicated using a Covaris ultrasonicator for 5 minutes with the following
settings: 10% duty cycle, 5 intensity, and 200 cycle/burst. Chromatin is diluted in 16.7mM
Tris-HCl pH 8.0, 1.2mM EDTA pH 8.0, 167mM NaCl, 0.01% SDS, 1.1% Triton X-100, and
cOmplete protease inhibitor from Roche and then pre-cleared with Protein A Dynabeads
for 1-2 hours. Protein A Dynabeads are bound to either pol II (Abcam ab5131 for Ser5p,
ab5095 for Ser2p, or Santa Cruz sc-899X for N-terminus) or control IgG antibodies for 1
hour, then washed 2x with 500μL PBS plus 5% bovine serum albumin (BSA). Diluted
chromatin is then bound to the antibodies overnight.
Once bound to beads, the sample is washed 2x each with a low salt buffer (20mM TrisHCl pH8.0, 2mM EDTA pH 8.0, 150mM NaCl, 0.1% SDS, and 1% Triton X-100), a high
salt buffer (20mM Tris-HCl pH8.0, 2mM EDTA pH 8.0, 500mM NaCl, 0.1% SDS, and 1%
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Triton X-100), and a LiCl buffer (10mM Tris-HCl pH8.0, 1mM EDTA pH 8.0, 250mM LiCl,
1% NP-40, and 1% deoxycholic acid). The cleaned beads are resuspended in 50mM TrisHCl pH 8.0, 10mM EDTA pH 8.0, and 0.1% SDS and the crosslinks are reversed
overnight. Proteinase K is used to digest the chromatin associated protein, and the DNA
is extracted with phenol-chloroform-isoamyl alcohol and precipitated with ethanol. A 2%
agarose gel is used to verify the crosslinked DNA, which should be between 200-400nt in
length. Sequencing libraries are made using the TruSeq ChIP Sample Preparation Kit
(Illumina) as per the manufacturer’s instructions.
Analytical Methods
PCPA Detection
Our discovery of PCPA with tiling arrays and HIDE-seq necessitated the development of
novel RNAseq analysis tools, as no existing ones could be easily adapted to detect the
phenomenon. After visualizing the RNAseq reads from U1 AMO treated samples on a
genome browser, the difference between PCPA and other transcriptomic changes was
clear. The next step was for me to translate these changes into a computational pipeline
that could be easily run for any sample. I structured the analysis with the following
parameters in mind: 1) detect as much of the PCPA as possible, especially the sets of
genes that we had already established as good markers from previous studies; 2) keep
the computational workload to a minimum due to the number of samples and sequencing
depth we were using; 3) reduce the number of false positives, arising most likely from
intron retention or transcriptional down-regulation; and 4) present the data in a format and
style usable by other lab or community members.
I first targeted the most unique and prominent feature of PCPA, which is the aggregation
of reads in the 5’ side of a gene, seen mostly in the first or second intron, followed by a
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decrease in signal over the rest of the gene body (Figure 2.1). I tested multiple methods
for detecting the site of read decrease at the PCPA point, including cumulative
distributions, inflection points, and sliding windows. These methods were either too
computationally intensive for the amount of data I was working with (50-200 million
paired-end reads) or were not sufficiently sensitive to detect the cases we were
expecting. As a consequence, I decided on a simpler approach of splitting the target
regions — initially introns — into a specific number of bins (i.e. allowing for variable
length), which would allow for play within the detection parameters. It was important to
pick an applicable number of bins per feature; if the number is too high, the bins’ small
size would mean that minor read changes could skew the results of any statistical tests.
Alternatively, if too few bins are used, their large regions could include too much
interfering signal against the read drop across a PCPA site and, consequently, reduce
the detection rate. Ultimately, trial and error showed that dividing intron one and two into
four equal size bins was the simplest approach that resulted in an acceptable number of
data points needed for further calculations. As there were some genes that did not show
a single PCPA site, but instead showed transcription degradation across the entire gene
body, this process was adapted by the postdoc Chao Di to utilize the entire gene length
rather than each intron separately. To avoid any genes expressed at low levels, any
gene with <10 reads in the first quarter of the target intron or gene body was removed.
Another important feature of PCPA that is included in the calculations is the decrease in
transcriptional output from the gene. That is to say, the full-length, spliced mRNA must be
decreased. To target this, I extracted multiple metrics for gene expression including exonexon junctions both across the entire gene and across our target exons (first, second, and
third); exon reads, especially terminal exon and coding sequence (CDS) reads; 3’UTR
reads; and general FPKM (fragments per kilobase per million mapped reads)
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measurements. Many of these metrics resulted in skewed results due to heavy read shifts
as a result of PCPA and splicing inhibition from U1 AMO. For example, FPKM
measurements are unreliable as a sizeable aggregation of reads in the first 5’ exon, due
to PCPA, could still result in the gene maintaining a high FPKM value despite not
producing functional mRNA. Similarly, the number of exon-exon junction reads, which are
valuable as a measure of fully processed mRNA, can be reduced due to splicing inhibition
from the U1 AMO and not PCPA. The simplest solution, therefore, is to compare the
terminal CDS to the first exon, which allows for direct assessment of the level of full-length
transcription to initiation, respectively. After U1 AMO, almost any increase in the signal in
5’ exons without a corresponding increase in terminal CDS would be due to PCPA, as
even partial transcription termination should produce more 5’ transcription at the expense
of full-length.
With the PCPA parameters defined as stated above, I then compiled the read values and
associated both the decrease in transcriptional output and fewer reads late in the gene as
compared with the initial exons. Comparing the values from the U1 AMO treated sample
to the control AMO treated sample allowed us to test for statistical significance in the
change across all genes in the samples using a Fisher’s exact test followed by BenjaminiHochberg multiple testing, with a cutoff of an adjusted P-value ≤ 0.01 (Benjamini and
Hochberg 1995). I worked with a postdoc in our lab, Chao Di, to apply these statistical
testing methods to the extracted values.
Intron Size Expansion
With our discovery that PCPA sensitivity was highly correlated with larger gene size, I
wanted to examine whether these genes most affected by U1 base-pairing inhibition were
also those that experienced the greatest intron expansion across vertebrate evolution (Oh
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et al. 2017). I decided to use gene ortholog data for this from Ensembl’s Biomart
(https://www.ensembl.org/biomart/martview) due to the inclusion of a large number of
organisms, variability in data features available, and the up-to-date reference genomes it
contains. With the initial RNAseq data from HeLa cells, I acquired each target organism’s
homology data in reference to the human genome, e.g. I downloaded feature data for all
genes in Drosophila melanogaster that were known to have a homolog in human. To
encompass multiple data points, I used fruit fly, Drosophila melanogaster; pufferfish,
Takifugu rubripes; zebrafish, Danio rerio; chicken, Gallus gallus; and mouse, Mus
musculus. Due to the many differences in curation and experimental knowledge on each
organism, I had to remove many duplicate gene and isoform entries. After cleaning the
data, I kept the longest isoform in order to maintain consistency with our previous
analyses. The finalized homology lists were then used to extract gene sizes for target
groups.
Novel Splice Site Usage and Multi-Exon Skipping
Despite the fact that much of our results with U1 AMO demonstrated high levels of PCPA
genome wide, we also anticipated there to be many splicing changes due to its role in
exon definition. As such, I decided to globally analyze splicing changes within our U1 AMO
datasets. Existing tools for measuring sample level splicing changes rely on previous gene
annotations, such as MISO (Katz et al. 2010), or are computationally intensive or slow,
such as JUM (Q. Wang and Rio 2018) or MAJIQ (Vaquero-Garcia et al. 2016); therefore,
I sought to develop a simple, gene-based tool for detecting splicing changes for all exon
junctions regardless of annotation. To reduce calculation time, rather than defining novel
splice junctions from scratch, I utilized TopHat’s (Trapnell, Pachter, and Salzberg 2009)
or STAR’s (Dobin et al. 2013) de novo splice junction algorithm via the spliced read files
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they output from alignment. To more easily work with the data, I started by removing all
reads that align canonically to consecutive exon-exon junctions in any isoform (i.e. a
spliced read that spans from exon 1 to exon 2). This is done simply by using genomic
coordinates of the splice location in both the BED entry and all introns in the genome. In
general, this removes >80% of spliced reads in most samples. The rest of the reads are
then filtered to reduce potential false positives due to sequencer or aligner error by
removing all junction sites containing >1-5 reads; this threshold depends highly on
sequencing depth. Once cleaned, the reads are processed into either splice junctions that
utilize both a known 5’ and 3’ss, and those that do not, again using genomic coordinates.
The former, if the 5’ and 3’ss are found to be within one gene, are considered multi-exon
skipping, otherwise they are labeled as run-on transcription and trans-gene splicing. The
latter are considered de novo splicing, and require further analysis to differentiate them
from what could be background signal or true novel splice site usage.
For comparison of a treatment versus control, all read values are normalized to the
sequencing depth. Then, splicing is compared on a gene by gene basis to determine which
genes experience more exon skipping or run-on transcription.
To examine splice site sequences for skipped or included exons, I extracted 9 nucleotides
from each 5’ss, three in the upstream exon and six in the intron, and 23 nucleotides from
the 3’ss, three in the downstream exon and 20 in the intron. To determine skipped exons,
I looked for exons that were entirely overlapped by the inter-splice distance, i.e. the space
between the start and end of the junction, of any de novo splice junction as called from
TopHat or STAR. For each organism, I grouped the exons into those that were always
included in the samples (control and any treatment) and those that were skipped, even if
this was in one sample but not others. Each splice site sequence was then scored into a
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position weight matrix and represented graphically into a logo using Biostrings and
seqLogo from Bioconductor in R (Bembom 2014; Huber et al. 2015; Pagès et al. 2017).
To score splice site consensus sequence, I took the sequences extracted above and
utilized the maximum entropy modeling software MaxEntScan (Yeo and Burge 2004).
Gene Neighborhood Distances
A particularly interesting and novel result from my U1 AMO treated mouse cell RNAsequencing experiments was that many PCPAed genes were located in close genomic
proximity to small, up-regulated genes. I decided to globally analyze this potential
phenomenon to see if, and how, transcription expression correlates with expression of
other nearby protein coding genes. I first had to remove most non-coding RNAs (e.g. micro
RNAs, uncharacterized LOC RNAs, predicted and pseudo genes, etc.) from a reference
file as many of these non-coding RNAs would show up as hits when checking a gene list
for neighboring transcripts, but have little to no experimental data to confirm their function
or expression patterns. It should be noted that some non-coding transcripts are of interest
to us, for example MALAT1, because of known function in cancer or other disease states
or as heavy binders of RBPs (Ji et al. 2003). This required the removal of most non-coding
RNAs to be done partially by hand, identifying either groups to remove in batch or singular
annotations to remove individually.
Once cleaned, I used BEDtools (Quinlan and Hall 2010) to extract the closest nearby gene
from the target list and to compute the intergenic distance between them. Due to the large
size of some genes, and importantly PCPAed genes, I needed to test this distance using
the TSS, the transcription end site (TES), or both sites together as the reference point for
finding the nearest genes. Ultimately, there was minimal difference between the results
from utilizing different reference points of the gene, and I decided on using both the TSS
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and TES as the reference points so as not to restrict the data any more than necessary.
The only remaining variables were the specific gene groupings to compare, as well as the
set to use as the reference point. To reiterate, the purpose of this study is to determine if
the expression of small, essential genes increased in transcription by being in proximity to
larger genes that would be PCPAed in the event of cell stimulation, stress, or activation.
As such, I ended up using the small (<12kb) genes that were up-regulated with U1 AMO
treatment as the reference set due to the fact that these would best mimic the genes that
benefit from a loss of U1 telescripting. For the test group, I use two sets of genes: the
down-regulated but not PCPAed, as well as the PCPAed and down-regulated. In order to
have a control intergenic distance, I checked both the up-regulated genes to themselves,
as well as compared two random sampling of genes to one another. For this sampling, I
randomly extracted 20% of the genes per chromosome and calculated their intergenic
distance. I calculated this for each chromosome separately in order to not overestimate
intergenic distances, and then calculated the median from these data.
Upstream Antisense Transcription
Recently it has been shown that promoter directionality and upstream antisense
transcription is known to be highly regulated by U1 levels (Almada et al. 2013). Following
with the gene neighborhoods analysis explained above, it made sense to pivot the already
written pipeline to target directly the upstream antisense region of protein coding genes. I
again started by removing the same non-coding RNA transcripts. At first, I worked to
examine whether upstream antisense (UA) transcription is affected by the presence of
previously annotated genes in the UA region. To do this, I created reference files that
either used a 10kb window UA to all genes or used a window ≤10kb that included the
entire region UA to the target gene up until it encountered another annotated transcript. I
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then checked for read coverage and read coverage change in these regions in the control
or U1 AMO treated samples, and compared the two methods against one another. Using
a set 10kb window, regardless of the presence of annotated transcripts, produced less
read number variation in comparison to only testing regions without any gene annotations.
This is most likely because these known transcripts contain their own promoters and are
less dependent on the promoter from the target gene. Because the interest here was in
detecting UA transcription changes from PCPA and not testing differences in promoters, I
decided to filter out all genes with overlapping or nearby (≤10kb) UA transcripts.
Once this set of reference genes was collected, I grouped those that experienced
transcriptional changes after U1 AMO treatment into four groups: either not PCPAed but
down-regulated or up-regulated, PCPAed, or unchanged. I then computed both the read
coverage and read coverage change within the UA region in four different size ranges:
0.3kb, 1kb, 5kb, and 10kb. This was done in order to examine how far reaching the effect
of PCPA or U1 AMO induced transcriptional changes was on UA transcription. A distance
of 1kb showed the most acute response to U1 AMO.
RBP XLIPseq Analysis
As we had many RNA cross-linking immunoprecipitations with high-throughput
sequencing (XLIPseq) datasets, I tried to develop a method that would both verify the
accuracy of the pull downs and identify potential snRNP interactors. With the large number
of gene and pseudogene copies for each snRNA, which often only vary by one nucleotide,
it was not feasible to use data aligned to the human genome (hg19 or hg38). During normal
alignment and processing, reads from snRNAs would be extremely similar in sequence to
gene copies and, thus, multimap to these multiple locations and not be included in the
final alignment. As a consequence, I downloaded all annotated sequences for
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spliceosomal snRNAs (U1, U2, U4, U5, U6, U7, U11, U12, U4atac, U6atac) and two nonspliceosomal snRNAs (7SK and 7SL) from Ensembl’s Biomart. I then collated these into
fasta files and annotation gene transfer format (GTF) files in order to create Bowtie 2
(Langmead and Salzberg 2012) alignment indexed files. These were then used to align
the XLIPseq or RNAseq reads. I also used more stringent cleaning of aligned reads by
removing reads less than 20 base pairs that did not align completely to only one sequence.
Once processed, I was then able to use R to plot the read density along each snRNA
sequence to identify binding locations of the XLIP’d proteins or to identify pre-snRNA
sequences in the sample.
In order to determine the RNA binding compared to mRNA output, I simply compared the
mapped reads per million (RPM) of each gene in the XLIPseq to the exon RPM value in
the 5 minute 5-ethynyl uridine (EU) pulse-labeled RNA. I used the latter sample as a
control in this case because the shorter labeling time is more comparable to the 10-minute
formaldehyde cross-linking time used in the XLIP data. For calculating the binding loss to
RNA after PCPA, I divided gene RPM for each XLIPseq in the U1 AMO treatment by the
same value in control.
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Figure 2.1 PCPA identification workflow for RNAseq data
(a) Description of the method used to identify the 5’ side read aggregation in PCPAed
genes. Blue brackets indicate the region of accumulated PCPA products as identified by
eye. Blue boxes indicate the quartile regions used for the calculation, also shown in blue.
(b) Description of the method used to identify the reduction in mRNA output from U1 AMO
treatment. Select exons used for this calculation are identified by blue arrows, the
calculation itself is also shown in blue. 30 minute labeled 4sU RNA from U1 AMO
transfected HeLa cells (red) is compared to control (black) for the indicated regions. For
gene structure lines depict introns, boxes depict exons, and thinner boxes depict UTRs.
Genomic distances are shown as dashed black lines.
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CHAPTER 3: CO-TRANSCRIPTIONAL U1 TELESCRIPTING
AND IDENTIFICATION OF PCPAED GENES
Chapter Details
Published in “U1 snRNP telescripting regulates a size-function-stratified human genome”
(Oh et al. 2017). Contributing members: Jung-Min Oh and Chie Arai (RNAseq, 3’RACE);
Chao Di (help with statistical significance testing and metagene profiling).
Detection of PCPA Events
While U1 telescripting was identified by the Dreyfuss lab in 2010 and expanded upon in
2012, the discovery was limited by the techniques available at the time (Kaida et al. 2010;
Berg et al. 2012). Advancements into RNAseq, already described in the Introduction,
allowed for concomitant advancements in analysis of new, large datasets. The critical first
step in understanding PCPA and its effect on the transcriptome was to identify which
genes were sensitive to U1 base-pairing inhibition. The process in its entirety is described
in more detail in the Methods section herein, but it is worthwhile to note again that the
analytical methodology underwent several revisions before it was finalized.
Briefly, the workflow targets two important changes in transcription related to PCPA: (1)
that full-length transcription is decreased by measuring the terminal CDS vs. the first CDS,
and (2) that there is a 5’ aggregation of reads in either the whole gene body or in one of
the introns (Figure 3.1). These calculations also work to exclude false positives due to
decreases in transcription initiation, which would show similar decreases in both the first
and terminal exon, as well as intron retention, which are exemplified by near flat levels of
intronic reads.
We applied the above criteria to recent 5nmol U1 AMO datasets from Jung-Min Oh and
Chie Arai, two postdocs in the lab (Oh et al. 2017). These experiments were carried out in
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HeLa cells with a 4 or 8-hour incubation time after U1 AMO transfection, and nascent RNA
was labeled for either 30 minutes or 2 hours with 4sU. The RNA was either selected using
oligo-dT beads to enrich mRNA with poly(A) tails, or simply depleted of rRNA to capture
the total RNA pools. I performed adapter trimming, quality control, and alignment of the
reads to the hg19 and hg38 reference genomes using TopHat and STAR. This resulted in
53-167 million mapped reads used for downstream analysis. I then applied the PCPA
detection algorithm and identified 3,590 PCPAed genes out of a total 9,744 expressed
genes (RPKM ≥ 1) from the 8-hour transfection time point, with a 90% overlap with the 4hour time point suggesting rapid PCPA onset after U1 AMO treatment (Figure 3.1; full list
of genes found in Supplementary Table 1). The identification of these PCPAed transcripts
was validated both by visualization of a large subsample of genes on the UCSC Genome
Browser, as well as by 3’RACE of select genes performed by Jung-Min Oh. Moreover, the
presence and position of these PCPAed transcripts were verified from data external to our
lab. For example, tissue-specific 3’ polyadenylated transcripts and binding locations of
cleavage and polyadenylation factors coincided with the PCPA sites in our samples (Derti
et al. 2012; Yao et al. 2012). As with our earlier studies, the polyadenylated nature of these
shortened transcripts further confirmed the PCPA mechanism to be due to PAS activation
by the CPA machinery, although we still lacked direct evidence that pol II disengaged from
the gene as it does at the canonical 3’ end. As a consequence, I decided to directly test
the effect of U1 AMO on pol II.
Co-transcriptional PCPA Detection with Pol II ChIPseq
I worked to target pol II molecules that were engaged in transcription through chromatin
immunoprecipitation followed by high-throughput sequencing (ChIPseq) after treatment of
either a control AMO or U1 AMO. This technique utilizes formaldehyde’s zero-distance
cross-linking followed by antibody pull downs to select for DNA sequences bound by a
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target protein. Using this technique, I pulled down pol II bound DNA using three antibodies:
one that was general for all pol II through its N-terminal domain, and two that specifically
target promoter proximal paused or actively elongating polymerases through CTD Ser2p
or Ser5p markers, respectively. An immunoglobulin G (IgG) antibody was used as a nonspecific control. As there was no lab protocol for this, I adapted already published
methodologies (Lee, Johnstone, and Young 2006; Sun et al. 2011; Weber,
Ramachandran, and Henikoff 2014). Testing of the protocol, antibodies, and AMO
treatment was done using qPCR on the promoter and exon 1 of the housekeeping gene
GAPDH. The AFM promoter was used as a negative control, as it does not express in
HeLa cells (Figure 3.2).
I processed and aligned the sequencing data as described above, resulting in 18-135
million mapped reads (Table 1). Background reads from non-specific antibody interactions
are to be expected in most IP experiments; as a result, I used the reads from IgG IP, in
both control and U1 AMO treatment, to remove unwanted signal from their corresponding
pull-downs and to detect true binding peaks using a model-based analysis of ChIPseq
(MACS) (Y. Zhang et al. 2008). Visualization of the cleaned data on the UCSC Genome
Browser showed positive results for the N-terminal antibody, however the Ser2p and
Ser5p pull downs did not have good coverage across genes (Figure 3.3). The lack of
adequate coverage was not surprising; previous studies have identified issues with these
types of pol II antibody studies, including the fact that phosphoepitope specific antibodies
can be affected by the phosphorylation state of neighboring peptides and that CTD specific
antibodies may be hindered by crosslinking of the CTD itself to CTD-binding proteins
(Mayer et al. 2010; Bowman and Kelly 2014). However, this resulted in an inability to
elucidate any mid-gene pausing related to PCPA. Despite this, the N-terminal antibody
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proved to contain enough information to demonstrate the dynamics of pol II transcription
after U1 AMO.
As I compared the ChIP signal to our RNAseq, it was apparent that inhibition of U1 base
pairing induces premature pol II termination. The level of pol II binding decreased to
background level usually within a short distance (~1-10 kb) downstream of the PCPA site.
This is similar to the already described torpedo model of 3’ termination, where the
polymerase continues past the PAS and the resulting unnecessary RNA is degraded by
the Xrn2 exonuclease (Connelly and Manley 1988; Fong et al. 2015; Nick J. Proudfoot
2016). U1 AMO treatment results in a peak of pol II signal in what is now considered a
“termination zone” and may work to facilitate 3’ end processing or polymerase release.
The similarity in my pol II signal within the premature termination zone further suggests
that these PCPAed transcripts are processed in a manner almost identical to those at the
canonical 3’ end (Figure 3.4). Between the TSS and RNAseq-derived PCPA site, the pol
II signal was unchanged or higher than that found in the control. This indicated that
transcription initiation was either unaffected or possibly increased by PCPA. The latter
result is likely explained by a reduced recycling time in pol II molecules due to the higher
turnover caused by PCPA. As more polymerases disengage within a few kb of the TSS,
their proximity to the promoter could increase the likelihood of re-engaging with the same
gene. Metagene plots of pol II signal across the PCPAed genes from the RNAseq data
show all these phenomena in detail (Figure 3.5).
The Relationship Between Gene Size and Function
The identification of PCPAed genes quickly led to the discovery that large genes were
disproportionately more affected by U1 base pairing inhibition in comparison to smaller
genes (Supplementary Table 1). While the median gene size of all the expressed genes
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in the HeLa RNAseq was 23 kb, PCPAed genes had a median size of 39 kb. In contrast,
non-PCPAed genes were much shorter, with a median size of 14kb (Figure 3.6a). This
was not entirely unexpected, as larger genes stochastically contain more PASs due to
their size, largely through an increase in intron length. Within our samples, I verified this
intron expansion and PCPA correlation from the expressed genes and found it to be very
high (Spearman correlation = 0.9994). It is also worth noting that intron number increases
with gene size, although this does not correlate as strongly as intron size to PCPA, where
over one third of all PCPA events occurred in the first or second intron.
A more striking result was discovered upon further examination of the smaller, PCPA
resistant gene group. There were many genes that not only escaped PCPA, but exhibited
increased expression levels without any apparent splicing deficit. These genes appeared
to be the counter to those that were PCPAed; as a result, we explored the functional
differences between the two sets of genes.
The large numbers for these groups made the use of GO software problematic, as its
results were not reliable and resulted in a wide range of functional groups. As a
consequence, we further stratified the groups by selecting the most up- and downregulated genes from both groups. Specifically, I took the top 50% of genes as ranked by
fold-change from the up-regulated or PCPAed groups, resulting in 493 and 3,134 genes,
respectively. The select groups were more manageable, and the software XGR produced
GO terms that were then easily summarized using a package called REVIGO (Fang et al.
2016; Supek et al. 2011). The non-PCPAed and up-regulated genes were highly enriched
in cell proliferation, stimuli response, and transcription factors, indicating their use in cell
stress response and general housekeeping. In contrast, PCPAed and down-regulated
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genes were more diverse, showing enrichment for neuronal development, cell division,
and DNA replication and repair (Figure 3.6b and c).
To get a sense of whether this size-function stratification was limited to PCPAed genes
and their unaffected counterparts, I expanded the analysis to the entire human genome. I
took the enriched GO term groups for the PCPAed and the up-regulated, non-PCPAed
genes and extracted all the genes that are categorized by each functional term. The
results indicated that the size-function relationship persisted regardless of the sensitivity
to U1 AMO in our experiments. For example, tissue differentiation or tissue specific genes
are highly enriched in large genes, while cell stimuli response and cell survival are found
more often in smaller genes. This implies that PCPA avoidance, by keeping introns small
so as to not stochastically generate many PASs, has played a role in the determination of
gene size. By maintaining a small size, primary-response genes could be transcribed
quickly and not worry about transcription loss due to PCPA. This theory will be discussed
in more detail in the next chapter.
These results shown here elucidate the process and important nature of U1 telescripting.
My pol II ChIPseq experiment demonstrated that transcript shortening is due to PCPA and
is co-transcriptional. Additionally, my analytical work allowed us to globally identify
PCPAed transcripts has opened the door for further scientific study into the specifics of
U1 telescripting. The establishment of U1 as a transcriptional regulator based on gene
size and function is, to my knowledge, the first of its kind. Through transcript length
dependent PCPA suppression, U1 can regulate not only transcription, but also gene
structure. I sought to examine this theory in more detail through a series of RNAseq
experiments of my own, as well as the creation of additional analytical programs.
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Figure 3.1 U1 base pairing inhibition rapidly induces PCPA in 5’ introns
Genome browser view of the gene EXT1 with 4sU labeled RNA from HeLa cells
transfected with either U1 (red) or control (black) AMO is shown as reads aligned to the
human genome (hg19). PCPA is demonstrated by the abrupt termination of reads in the
U1 AMO transfected tracks in the large first intron. The height of each RNAseq track is
scaled to the same value in this figure to demonstrate the large accumulation of reads in
the 5’ region of the gene due to PCPA. CstF64 iCLIP binding site peaks are shown in blue,
and poly(A) sites detected in various human tissues are shown as vertical black bars (Yao
et al. 2012; Derti et al. 2012). Numbers to the left of the read distributions show the highest
peak height value in the field as normalized to the total mapped reads. For gene structure,
lines depict introns, boxes depict exons, and thinner boxes depict UTRs. Genomic
distances are shown as dashed black lines.
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Figure 3.2 Pol II ChIP RT-qPCR
Pol II binding counts to DNA from HeLa cells in GAPDH promoter (yellow) or exon 1 (blue)
after formaldehyde cross-linking are shown normalized to the signal from the AFM
promoter (red) which does not express in HeLa. Three pol II antibodies (N-terminus,
Ser2p, and Ser5p) are shown, as well as IgG as a non-binding control. Error bars depict
the standard error from the triplicate experiment.
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Figure 3.3 Pol II ChIPseq
Genome browser view of the gene E2F3 with pol II ChIPseq data from HeLa cells
transfected with either U1 (red) or control (black) AMO is shown as reads aligned to the
human genome (hg19). Numbers to the left of the read distributions show the highest peak
height value in the field as normalized to the total mapped reads. For gene structure, lines
depict introns, boxes depict exons, and thinner boxes depict UTRs. Genomic distances
are shown as dashed black lines. Pull-down data was normalized to the relevant IgG
control (U1 or control AMO transfection) using MACS v1.4.4 (Y. Zhang et al. 2008).
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Figure 3.4 U1 base pairing inhibition prematurely terminates pol II in gene bodies
Genome browser view of the genes E2F3 and RAB7A with pol II ChIPseq and 30 minute,
4sU labeled RNAseq data from HeLa cells transfected with either U1 (red) or control
(black) AMO is shown as reads aligned to the human genome (hg19). Blue boxes highlight
the termination zone, and show the similar decline of pol II signal past the TES and PCPA
point in control or U1 AMO transfected samples, respectively. CstF64 iCLIP binding site
peaks are shown in blue, and poly(A) sites detected in various human tissues are shown
as vertical black bars (Yao et al. 2012; Derti et al. 2012). Numbers to the left of the read
distributions show the highest peak height value in the field as normalized to the total
mapped reads. For gene structure, lines depict introns, boxes depict exons, and thinner
boxes depict UTRs. Genomic distances are shown as dashed black lines. Pull-down data
was normalized to the relevant IgG control (U1 or control AMO transfection) using MACS
v1.4.4 (Y. Zhang et al. 2008). Figure is adapted from Oh et al. (Oh et al. 2017).
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Figure 3.5 PCPA is co-transcriptional
Metagene plot of pol II ChIPseq data from PCPAed identified genes from either U1 (red)
or control (black) AMO transfected HeLa cells. Plot is shown with absolute distances
around the TSS (1,000bp upstream, 500bp downstream) and TES (500bp upstream,
1,000bp downstream), which are depicted as blue dashed lines. The remaining region of
the gene body, between the two black dashed lines, is scaled to 2,000bp for all genes in
the analysis. Pull-down data was normalized to the relevant IgG control (U1 or control
AMO transfection) using MACS v1.4.4 and the metagene profile was generated using
CGAT v0.2.5 (Y. Zhang et al. 2008; Sims et al. 2014). Figure is adapted from Oh et al.
(Oh et al. 2017).
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Figure 3.6 Gene size and function are stratified by sensitivity to U1 base pairing
inhibition
(a) Boxplots showing the gene size distribution in all expressed genes (white; RPKM ≥ 1;
n = 9,744, median size = 22.8kb), PCPAed genes (yellow; n = 3,590, median size =
39.0kb), or non-PCPAed and up-regulated genes (blue; n = 988, median size = 6.8kb)
from 30 minute, 4sU labeled and U1 AMO transfected HeLa cells compared to control. (b)
Histogram showing the GO term enrichment (p < 0.05) for non-PCPAed and up-regulated
or PCPAed and down-regulated genes. Enrichment was calculated using the XGR tool
and further functional classification was performed using REVIGO (Fang et al. 2016;
Supek et al. 2011). The –log2(p-value) for top 50% of genes as ranked by fold change for
each group is shown. (c) Boxplots showing the gene-size distribution for all human genes
classified in the functional groups depicted in b. Median size for functional groups enriched
in non-PCPAed and up-regulated genes is 23kb, while median in PCPAed and downregulated genes is 38kb. Figure is adapted from Oh et al. (Oh et al. 2017).
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Table 1 Pol II ChIPseq mapping statistics
Numbers for the hg19 read alignment of pol II ChIPseq using TopHat v2.1.1 (Trapnell,
Pachter, and Salzberg 2009). Multi-mapped reads are defined as those which align to 20
or more locations in the genome.
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CHAPTER 4: TELESCRIPTING IS EVOLUTIONARILY CONSERVED AND
STRATIFIES GENOME BY GENE SIZE-FUNCTION
Chapter Details
Published in part in “U1 snRNP telescripting regulates a size-function-stratified human
genome” (Oh et al. 2017). Contributing members: Jung-Min Oh and Chie Arai (RNAseq,
3’RACE); Byung-Ran So and Jiannan Guo (XLIPseq); Chao Di (help with metagene
profiling and XLIPseq binding calculations).
Gene Size Conservation
The segregation of gene function by size was of interest, at first, due to our interest in a
common gene structure found in higher eukaryotes: the majority of intronic sequence in a
gene is from extremely large 5’ side introns, typically the first (Figure 4.1a) (Gelfman et al.
2012). We reasoned that this particular layout in many genes was due to the function of
U1 telescripting, as the cryptic PASs in the large 5’ introns would be actionable for PCPA
early in transcription. This would allow for PCPA to terminate pol II elongation within a
matter of minutes, rather than other mechanisms of transcription regulation that could take
hours to show cellular affects due to transcribing polymerases stuck in large genes, if the
actionable PASs were instead clustered in large 3’ introns one or two hundred kb from the
TSS. More specifically, we hypothesized that genes that would be immediately necessary
for cell survival or activation in the event of specific stimuli or stress would maintain their
small size due to evolutionary pressure to avoid PCPA from an actionable PAS. Genes
that are not required for short-term cell survival, however, were selectively allowed to
increase in size through intron expansion, which has been very significant to the gene
structure in complex vertebrates (Catania and Lynch 2008; Rogozin et al. 2012). I decided
to test this hypothesis using analytical methods from the RNAseq data that we currently
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had in HeLa, discussed in the previous chapter, and additionally perform similar U1 AMO
experiments on three different cell lines: S2 (Drosophila melanogaster, fruit fly), ZF4
(Danio rerio, zebrafish), and NIH-3T3 (Mus musculus, mouse) cells.
Gene Size Expansion
I first decided to try and understand how both the PCPAed and up-regulated genes had
changed in size evolutionarily. To do this, I obtained gene homology data from Ensembl
and compiled lists of gene sizes across multiple organisms referencing their orthologs that
were found in humans. From these data, I extracted all of the genes from different groups
as identified in our HeLa U1 AMO: PCPAed, PCPAed and down-regulated (PCPA-down),
non-PCPAed (unchanged), non-PCPAed and up-regulated (UP), and all expressed genes
(i.e. RPKM ≥ 1). I reasoned that the most impactful of these for my analysis would be the
groups most affected from U1 base-pairing inhibition; as a consequence, I focused on the
PCPA-down as well as UP gene groups, with a baseline comparison of all expressed
genes (Supplementary Table 1). Plotting the distributions of gene size versus phylogenetic
distance from human displayed a striking difference between these two groups. The UP
genes remained smaller in size than the PCPA-down genes across all the organisms I
tested. Moreover, there was a very minor change in their small size throughout the
organisms, with a standard deviation of 3.9kb (1.5-11kb). In comparison, orthologous
genes from the PCPA-down group showed a strong expansion of gene size across
evolution, from 6kb in fly to 43.6kb in mouse with a standard deviation of 12.3kb (Figure
4.1b).
Taken together with the previous results of the functional differences between small and
large genes, the marked distinction between the intron expansion in PCPA-down genes
and the lack of such expansion in UP genes demonstrates selective evolutionary pressure
62

for gene size based on function. This provides an alternative solution to the current
theories regarding intron size and the purpose of intron expansion, particularly in early
introns. The most common of these theories are: the selection hypothesis, which holds
that evolution has selected for compact genes to reduce transcription time and energy
expenditure; and the genomic design hypothesis, which postulates that gene size is
regulated by the need for time-dependent expression control and the inclusion of
regulatory elements in introns (Rogozin et al. 2012). Selective intron expansion, to benefit
small genes, seems more likely when one takes into consideration our earlier experiments
with cell activation, which demonstrated mild PCPA and 3’UTR shortening in some select,
large genes after transcription up-regulation (Berg et al. 2012). This physiologically
relevant experiment suggested that large genes could be sacrificed in the event of cell
activation or the stress response, in order to allow, or even facilitate, small genes to be
expressed when needed.
Large Genes Sequester RNA Binding Proteins
Concurrent to my analytical work on the expansion of intron size, Byung-Ran So and
Jiannan Guo, two post-doctoral colleagues in the lab, performed a series of high (5nmol)
U1

AMO

experiments

with

low

concentration

formaldehyde

crosslinking

and

immunoprecipitation (XLIP) followed by both high-throughput sequencing (XLIPseq) and
mass spectrometry (MS). This ribo-proteomic strategy takes advantage of formaldehyde’s
ability to induce protein-protein and protein-RNA crosslinking to capture both the protein
composition and stoichiometry of complexes associated with the target protein, as well as
to determine their binding location on RNA (Yong et al. 2010). In order to verify the
specificity of each antibody and the stringency of the wash steps, I compiled the
sequences of all known spliceosomal snRNA isoforms and used these as a reference to
align the XLIPseq data (Figure 4.2a). There are a large number of snRNA gene copies
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and pseudogenes found in the genome with only minor differences between them, often
changes of only 1-2 base pairs. As such, during normal alignment and processing, many
reads associated with these snRNAs are discarded as multi-mapping reads due to the
alignment algorithms. By aligning directly and specifically to the snRNA sequences, I was
able to more accurately represent the amount of snRNPs included in each of the pulldowns. This alignment method worked well to demonstrate the validity of the experiment,
as spliceosomal proteins demonstrated strong enrichment in snRNA reads with their
known interactors. Conversely, non-spliceosomal proteins, such as hnRNPs or the SP2/0
control antibody, did not show high snRNA read enrichment as expected.
While there were many different antibodies used to target a range of RBPs, I examined
the general differences between two groups: the hnRNPs (hnRNPA1 and hnRNPC) and
the splicing factors (SFs) (SF3B1, U2B”, U1A, and U1C). Because of their separate,
general binding locations on genes seen in the XLIPseq. hnRNPA1 and hnRNPC interact
with pre-mRNA and bind preferentially to introns, whereas SFs are seen near splice sites
and across exons (Figure 4.2b). I also included in my calculations the input RNA, a nonspecific SP2/0 antibody pull-down, and 5 minute 5-ethynyl uridine (EU) pulse-labeled
RNA, both rRNA depleted (total) or poly(A) selected (mRNA) as control samples. The
latter is helpful for comparison because the shorter labeling time is more similar to the 10minute formaldehyde cross-linking time as opposed to the longer (30 minute or 2 hour)
labeling times used in earlier experiments. Visualization on the UCSC Genome Browser
showed the specific binding locations of the protein binding, as hnRNPC was present
across nearly the entire pre-mRNA strand, in comparison to the exon-centric SFs (Figure
4.3a). Metagene analysis across splice sites provided further granularity, demonstrating
that hnRNPC was not only enriched in introns, but excluded from exons (Figure 4.3b).
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This result supports the theory that the exon definition complex, i.e. SFs and snRNPs,
evicts hnRNP proteins prior to splicing (Wongpalee et al. 2016).
In order to determine whether hnRNP and SF binding contributed to mRNA output, I
normalized the binding signal for these proteins based on the mRNA output for each gene
as measured by exon reads from the EU RNA. When broken down by gene size into 10
bins of equal gene number, it was clear that larger genes bound a significantly large pool
of hnRNPs. Specifically, the largest 20% of genes bound >50% of the total hnRNPC on
pre-mRNA, but these genes did not exhibit a proportional increase in mRNA level (Figure
4.4a). In smaller genes, hnRNPs were under-represented in comparison to SFs when
normalized to the mRNA. A potential (and tempting) explanation for this result is that the
large introns sequester several processing factors during transcription due to their larger
size and higher number of exons. However, the fact that this increased binding does not
stimulate mRNA production suggests that these excess proteins may not be necessary
for transcription, but instead may serve another function. For instance, during cell
stimulation or activation, both of which cause minimal PCPA and 3’UTR shortening, as
explained earlier, the 3’ transcription loss from PCPA would then free up a portion of these
processing factors that would normally be bound to the RNA of large genes. Not only
would this affect hnRNPs, due to the loss of large introns, but SFs as well, due to the
higher density of exons in the 3’ ends of genes (Bradnam and Korf 2008; Gelfman et al.
2012). Thus, large genes serve, additionally, as sponges, or as a reserve of various RNA
binding proteins. Under stress or cell activation conditions, these proteins would be
released from PCPAed transcripts and could be utilized by small, acute response genes
to boost their transcriptional output.

65

In order to investigate how much protein binding is lost after PCPA, I calculated the change
in sequencing depth normalized reads between control and U1 AMO samples for each
XLIP. For this calculation, I used only genes that experienced substantial or near complete
PCPA, as determined by a >90% decrease in last exon versus first exon read signal from
the EU labeled RNA. Breaking the data down into the gene size bins as used above
showed that there was significant loss of hnRNPC binding (>10 times) in the largest gene
group when compared with those at median size (24kb) or lower (Figure 4.4b). PCPA
induced U1C binding loss, by comparison, was not affected by gene size. Taken together,
these observations suggest that large genes hoard certain pre-mRNA processing proteins,
specifically hnRNPC.
Recent research has demonstrated not only that RNA processing factors are limited in
quantity within a cell, but also that their levels can be insufficient for splicing and
processing in certain instances such as meiosis, transcriptional up-regulation, or
sequestration due to micro-satellite repeats (Miller et al. 2000; Munding et al. 2013). In
comparison to these instances, transcription of large genes can bind many more RBPs
given their size alone and yet this resource hoarding is constant in many cells. The
sensitivity of large genes to U1 levels relative to transcription, for example in neuronal
activation, that leads to even a moderate amount of PCPA could free up many RNA
processing resources for use by other, smaller genes (Berg et al. 2012; Oh et al. 2017).
Given the size-function stratification mentioned previously, this further supports a
mechanism by which non-vital large gene transcription is sacrificed through PCPA during
cell stimulation to provide a rapid boost to acute response genes. The common
asymmetrical architecture of genes with higher 5’ intron density and 3’ exon density would
maximize this mechanism when large genes PCPA early and thereby shorten the lag time
in resource turnover.
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Organismal RNAseq
Armed with the indirect analytical results that demonstrated intron expansion in PCPAed
genes, it was important that I directly examine whether global U1 AMO induced PCPA
was isolated to HeLa cells. While we had previously shown that this intron expansion
occurs in fruit fly and mouse, these data were not directly comparable to our current
RNAseq data and were limited in breadth due to the technology (Berg et al. 2012). To
expand on our earlier research, I chose to revisit the mouse and fruit fly systems using the
primary NIH-3T3 fibroblast and S2 embryonic cell lines, respectively. I also decided to use
a zebrafish cell line, ZF4 embryonic fibroblasts, as its genome was well researched, there
was already well-established work with morpholinos, and a few recent spliceosome
studies had used zebrafish (Nasevicius and Ekker 2000; Trede et al. 2007; Rösel et al.
2011). In order to be consistent with previous experiments in HeLa cells, I included two
U1 AMO time points, at 6 and 8 hours. In addition, I examined if there were any early U1
level sensitive genes in these organisms. I also tested three labeling time points (30, 60,
and 120 minutes) so as to be able to isolate both a more accurate snapshot of nascent
transcription with the shorter label and also test the data against our older, 120 minute
labeled samples.
Before I began my experiments, lab protocol for nascent RNA isolation called for the
removal of rRNA prior to 4sU labeled RNA purification. This works well in the highly active
HeLa cell lines that were our primary experimental foundation in vitro. As these are a
highly aggressive and metabolically active cancer cell line, there has never been an issue
in the lab with acquiring usable amounts of RNA for experiments using this approach.
During the course of my tests with alternative, less active cell lines, such as fibroblasts, I
discovered that there was less labeled RNA over the same time period in comparison to
HeLa cells. Combined with a maximum input limit for the rRNA removal kits, primarily due
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to the binding limit of anti-rRNA sequences on the beads, I would have required
extraordinary amounts (10-20x) of harvested cells in order to acquire enough labeled RNA
for research purposes. Instead, I reversed the purification procedure by first selecting for
the labeled RNA. This was achievable due to the stringent and multi-step washing
procedure used in the 4sU selection. In doing so, I was able to achieve greater amounts
of purified RNA for both PCR and RNAseq from my quiescent cell lines. RNA quality and
purity was verified using an Agilent Bioanlyzer, which confirmed the efficacy of this new
method.
I verified the efficacy of the U1 AMO treatments in mouse and fly using RT-qPCR on genes
identified as PCPAed from our earlier HIDE-seq experiments. For these validations, I used
a 5nmol U1 and control AMO dose to induce strong PCPA and to remain consistent with
the previous experiments done in HeLa cells. I targeted specific gene regions by using
primers to the first intron upstream of the PCPA site as well as either the junction between
exon 1 and exon 2 or both exons separately (Figure 4.5; full data in Table 2). Most time
points in the mouse system showed increased intronic signal compared to exon signal
after U1 AMO treatment, indicating PCPA within the target genes. Notably, there were a
few outliers that exhibited minimal change or even increased exonic signal over the intron.
This is most likely due to incomplete purification of 4sU labeled RNA, which would result
in contaminant mRNA that had not yet been turned over within the cell. Two genes used
in the fly sample showed clear PCPA, however the gene Ten-m had increased exonic
signal. The latter utilized separate upstream and downstream exon primers for the PCR,
as an exon-exon junction spanning primer set was suboptimal in GC content and melting
temperature. As a result, it is unclear whether this increase in exonic signal is due to a
failed U1 AMO treatment, signal aggregation due to PCPA within the first and second exon
regions, or if the gene even PCPAs at all.
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Given the overall positive RT-qPCR results, I decided to proceed onto library preparation
and RNA-sequencing with the 6 hour U1 AMO treatment time points using 30 minute, 4sU
labeled RNA. Along with the high, 5nmol dose described earlier, I included a low, 1nmol
U1 AMO treatment in order to check for 3’UTR shortening as had been described
previously (Berg et al. 2012). After sequencing, the reads were cleaned of any adapter
sequence and aligned to the most up-to-date reference genomes for fly, zebrafish, and
mouse (dm6, danRer10, and mm10, respectively) as described previously (Oh et al.
2017). Multi-mapped reads were removed, resulting in between 50 and 175 million
mapped reads per sample (Figure 4.6; Table 3). For downstream analysis, read signal for
each sample was normalized to its sequencing depth as mapped reads per million (RPM).
Initial analysis of the data revealed that high and low U1 AMO concentrations induced
extensive down-regulation in mouse and zebrafish, consistent with the results from our
previous experiments in HeLa cells (Table 4). Both fly and mouse presented moderate
numbers of up-regulated genes as well, although zebrafish had many fewer than I
expected. A potential explanation for this would be a loss of RNA material during the
purification and selection process, leading to increased sequencing of background,
intergenic RNAs. However, this was not reflected in the alignment distribution of the reads.
Instead, the distribution showed only a slight increase in intronic and intergenic reads after
U1 AMO treatments. Further study into the mRNA output from zebrafish showed that both
U1 AMO doses decreased the overall splicing significantly more than either fly or mouse
(Figure 4.7). While I understood that U1 base-pairing inhibition would reduce splicing, the
level to which it was seen in zebrafish, and only in zebrafish, was surprising. Depicting the
read distribution in a metagene analysis revealed global loss of transcription in the 3’ end
of exons and introns in zebrafish when compared to mouse and fly (Figure 4.8). As our
PCPA detection algorithm is quite stringent, it is highly likely that a large number of genes
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experience low levels of background PCPA that escape our statistical and transcription
decrease cutoffs. This would reduce the overall splicing amount and number of genes
detected as up-regulated.
In the fly system, it was apparent that the response to the U1 AMO dose was much more
attenuated than in the other organisms. When viewing these data in comparison to
zebrafish, mouse, and human models, moderate PCPA and down-regulation could be
explained either by incomplete U1 AMO treatments or that telescripting and transcription
in general is not as dependent on U1 levels. Past experiments in the lab, confirming the
AMO dose response for U1 5’ sequence occupancy, did not include a fly cell It is also
possible that the transfection I performed was not of very high efficiency. As the mouse
and zebrafish AMO treatments worked well, I proceeded with downstream analysis in all
samples.
Visualization of the data using the UCSC Genome Browser confirmed the expected PCPA
with high, 5nmol U1 AMO in zebrafish and mouse at similar levels as those observed in
HeLa cells, but the fruit fly sample showed very minimal PCPA. Global analysis using the
calculations described previously confirmed these results (Table 4). Moreover, analyzing
the gene sizes for the up group compared to those that are PCPA-down showed the same
size stratification as we had published previously (Figure 4.9; numerical data in Table 5)
(Oh et al. 2017). It is important to note that the size of PCPA-down genes increases from
fly to zebrafish to mouse, from 16kb to 23kb and 41kb, respectively. In comparison, up
genes increased only 1.5kb to 11kb and 7kb across the same organisms, while expressed
genes increased from 2kb to 12kb and 17kb. This was expected based on my previous
analytical work examining orthologs from the human PCPA-down genes. This size
increase may be the primary explanation behind the lack of PCPA in fly, which have much
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smaller genes overall. The median size of PCPA-down genes in the other organisms, 2043kb, is significantly larger than what is seen in fly, 6-16kb.
To examine the conservation of U1 level sensitivity, I compared overlap of the high U1
AMO induced PCPA-down genes between these three organisms against those in human
using ortholog data from Ensembl (Table 4). These results showed a significant level of
overlap between the PCPA-down genes (30-44%, hypergeometric test p-value < 0.05) for
mouse and zebrafish; fly, however, showed non-significant minimal overlap to human (1720%, hypergeometric test p-value 0.099-0.394). Moreover, when I visually examined
some of these overlapping genes on the genome browser, the PCPA site occurred at a
similar location within the gene across organisms (Figure 4.10). The ortholog overlap in
up genes was significant for all samples (3-34%, hypergeometric test p-value < 0.05),
when compared to human. When taken together, these data demonstrate the
evolutionarily conserved function of telescripting. The conservation in both PCPA-down
and up also strengthens the theory that the boost in small, acute response genes is
possible, at least in part, by the transcription decrease from telescripting loss.
Gene Neighborhoods
When examining the PCPA-down genes in mouse on the UCSC Genome Browser, I noted
the prevalence of small, up-regulated genes nearby (that is, ~5-50kb away) (Figure 4.11).
Given the above conclusions from the hnRNP XLIP and gene size-function analysis, I
postulated that the two, contrasting gene groups were positioned in close proximity
globally within the genome. To address this, I searched for the closest nearby transcript
to each up-regulated gene. I decided to use these as the reference point rather than the
PCPA-down genes, as I reasoned this would better demonstrate whether the upregulation in small genes could be explained from the loss of transcription in PCPA-down
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genes. As comparisons, I also did the same analysis for up-regulated genes to other upregulated genes (UP-UP) and up-regulated to down-regulated (UP-DOWN). For a control,
I randomly sampled genes on each chromosome, with the number weighted based on the
number of genes each chromosome contains. Calculating the median intergenic distance
between these groups demonstrated that up-regulated compared to PCPA (UP-PCPA)
and UP-DOWN were significantly closer than both the control and UP-UP distances
(Figure 4.12; numerical data in Table 6).
The shorter intergenic distances between UP-DOWN genes was surprising and consistent
among all species. This provides more support for the resource sequestration idea
suggested earlier; that a transcription decrease of any kind may contribute to up-regulation
in nearby genes by freeing up RNA processing factors. Genes unaffected by the
mechanism of decrease, in our case by being insensitive to U1 base pairing inhibition, are
able to take advantage of resources freed up by neighboring genes. Of course, this does
not imply that genes would be required to be in close proximity in order to benefit from
these resources, as there are examples of both PCPA-down and up genes that are not
near to one another. The generally smaller intergenic distances, however, support the idea
that adjacency is beneficial to the small genes, most likely by reducing the distances over
which the freed resources must disperse before being available for use. As these
calculations only take into account linear distance, and not the three-dimensional space
that results from chromatin looping, they act only as a rough measurement for proximity
in the nucleus.
Upstream Antisense Transcription
Recently it has been shown that promoter directionality is controlled by U1, as sense
direction DNA (i.e. downstream of the TSS in the gene body) contain a higher ratio of
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strong U1 binding sites to PASs (Almada et al. 2013). Conversely, the region upstream
antisense (UA) of the TSS contains a higher number of strong PASs and fewer U1 binding
sites. This allows for early transcription termination in the UA direction, while preserving
telescripting within the gene body. The method by which I compiled the analytical work for
gene neighborhoods made it very simple to adapt the protocol to examine UA transcription
in my organismal RNAseq samples or any other data from the lab. To do this, I extracted
a 1kb UA region from all protein coding genes that did not contain another overlapping,
annotated transcript. I filtered out genes with previously annotated upstream transcripts
because I worried that these would be under the control of their own, independent
promoter. Roughly half of expressed genes across all organisms tested contained a UA
protein coding gene or non-coding RNA (ncRNA).
When taking into consideration the pol II ChIPseq, I anticipated that U1 AMO induced
PCPA would increase the UA transcription since it caused a slight increase in pol II
initiation and promoter proximal pausing. To verify this, I analyzed all UA regions broken
down by the status of the sense gene transcript after U1 AMO into either: unchanged, upregulated, down-regulated but not PCPAed, or PCPAed. The results verified my
hypothesis and also demonstrated that sense direction transcription throughput is
indicative of UA transcription as down-regulated genes showed a strong decrease in UA
signal and vice-versa for up-regulated genes (Figure 4.13). This supports the recent
studies done on divergent transcription, which claim that most promoters allow
polymerases to engage bi-directionally and that the U1 or nucleosome structure then
dictate which direction transcription is allowed to continue (Seila et al. 2009).
My experiments with U1 AMO in multiple organisms have further confirmed the presence
of U1 telescripting outside of the human system. More importantly, they have
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demonstrated the evolution of gene size-function stratification caused by U1. My analysis
of disproportionate hnRNP binding, specifically hnRNPA1 and hnRNPC, and the shift of
these RNA processing resources from large genes to small genes with U1 AMO, suggest
a new explanation as to how the small genes increase mRNA output with U1 base pairing
inhibition. This explanation is further supported by the proximity of these small genes to
large, RBP rich and U1 AMO sensitive large genes in linear genomic space. The work I
have done here helps to cement U1 as a global regulator of transcription, as well as a
potential regulator of gene and genome structure, through its function in telescripting.
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Figure 4.1 U1 telescripting facilitated first intron and gene size expansion
(a) Line graphs showing the average intron size in base pairs for all genes in Drosophila
melanogaster (Fly; green; dm6), Danio rerio (Zebrafish; blue; danRer10), Mus musculus
(Mouse; red; mm10), and Homo sapiens (Human; black; hg19) genomes. Only the first 20
introns of each gene are shown. Vertical lines at each position represent the confidence
interval. (b) Density plots showing the gene size distributions for human gene orthologs
for genes that were either not-PCPAed and up-regulated (blue) or PCPAed and downregulated (yellow) after 5nmol U1 AMO transfection in HeLa cells. Distributions are shown
for Drosophila melanogaster (Fly), Takifugu rubripes (Pufferfish), Gallus gallus (Chicken),
Mus musculus (Mouse), and Homo sapiens (Human). Figure panel adapted from Venters
et al. (Venters et al. 2019).
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Figure 4.2 XLIPseq alignment validates cross-linking procedure
(a) Stacked bar graphs showing the number of reads aligned to each collection of
spliceosomal snRNA sequences (U1, red; U2, green; U4, blue; U5, orange; U6, purple)
normalized to the total mapped reads (hg19 and snRNA reads combined). (b) Stacked bar
graphs showing the distribution of XLIPseq and RNAseq read alignment locations (intron,
blue; CDS, yellow; UTR, red; intergenic, green) as a percentage of the total aligned reads.
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Figure 4.3 hnRNP proteins are excluded from exons
(a) Genome browser views for the genes GALNT2 (left) and DYRK1A (right) with XLIPseq
(IP) or RNAseq (RNA) read distributions for control samples (black), mRNA/exon centric
binding factors and poly(A) selected mRNAseq (blue), or pre-mRNA binding factors and
total RNAseq (red) from HeLa cells aligned to the human genome (hg19). Numbers to the
left of the read distributions show the highest peak height value in the field as normalized
to the total mapped reads. For gene structure, lines depict introns, boxes depict exons,
and thinner boxes depict UTRs. Genomic distances are shown as dashed black lines. (b)
Metagene plots for XLIPseq read distributions across 3’ splice sites (blue) or 5’ splice sites
(red). Read signal was normalized to SP2/0 and metagene profile was generated using
CGAT v02.5 (Sims et al. 2014). Plotted region includes the 150bp intronic region and 75bp
exonic region around each splice site.
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Figure 4.4 Large genes sequester disproportionate amounts of hnRNPs
(a) Point and line graph showing the XLIPseq binding signal of hnRNPC (red), U1C (blue),
and SF3B1 (green) normalized to the mRNA output as measured by exon signal from
poly(A) selected and 5-minute, EU labeled RNAseq data. This binding is calculated for ten
gene size bins of equal number. Points represent the mean binding signal, and the line
represents the best fit line for these points. (b) Bar graph showing the loss of binding for
hnRNPC (red) and U1C (blue) over the same gene size bins as in panel a. Binding loss
was calculated as the difference in XLIPseq gene reads from U1 versus control AMO
transfected HeLa cells.
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Figure 4.5 Mouse and fly RT-qPCR
RNA relative quantification data from U1 or control AMO transfected NIH-3T3 (Mouse,
top) or S2 (Fly, bottom) cells in three genes for each organism. Primers for either the first
intron (red) or the exon 1 to exon 2 junction is shown to quantitate the PCPA to spliced
mRNA ratio, respectively. Quantification is normalized to the control AMO transfected
intron 1 signal. Error bars depict the standard error from the triplicate experiment.
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Figure 4.6 Organism RNAseq read alignment distribution
Stacked bar graph showing the distribution of RNAseq read alignment locations (intron,
blue; CDS, yellow; UTR, red; intergenic, green) as a percentage of the total aligned reads.
Reads were aligned to either mm10 for mouse, danRer10 for zebrafish, or dm6 for fly.
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Figure 4.7 U1 AMO causes significant, global splicing inhibition in zebrafish
Boxplots showing the log2 fold change in 30 minute, 4sU labeled RNAseq exon-exon
junction reads from either down-regulated (red) or up-regulated (blue) genes in U1 versus
control AMO transfected cells for S2 (Fly), ZF4 (Zebrafish), or NIH-3T3 (Mouse) cells.
Gene expression changes were calculated using exon RPKM values tested for
significance using a Poisson test with a p-value < 0.01 threshold. Distribution differences
between the up- and down-regulated gene groups were tested for significance using a
Student’s t-test. A horizontal dashed line represents the 1-fold change line.
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Figure 4.8 U1 AMO causes global 3’ transcription loss
Metagene plots showing the exon and intron read distribution in control (black), 1nmol U1
(blue), or 5nmol U1 (green) AMO transfected S2 (Fly), ZF4 (Zebrafish), or NIH-3T3
(Mouse) cells from 30 minute, 4sU labeled RNAseq data. Exons and introns for all genes
were joined in consecutive order and these regions were then scaled to 2,000bp. RNAseq
reads aligned to each reference genome were normalized to the total mapped reads from
each sample. Metagene profiles were generated using CGAT v02.5 (Sims et al. 2014).
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Figure 4.9 U1 inhibition selectively PCPAs large genes across evolution
Boxplots showing the gene size distribution in all expressed genes (white; RPKM ≥ 1),
PCPAed genes (yellow), or non-PCPAed and up-regulated genes (blue) from U1 versus
control AMO transfected S2 (Fly, top), ZF4 (Zebrafish, middle), or NIH-3T3 (Mouse,
bottom) cells from 30 minute, 4sU labeled RNAseq data. Distribution differences between
the all expressed and two other gene groups were tested for significance using a Student’s
t-test.
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Figure 4.10 PCPA susceptibility is evolutionarily conserved
Genome browser view for the genes EXT1 and ARID1B with 30 minute, 4sU labeled
RNAseq read distributions for control (black) or U1 (red) AMO transfected cells from three
organisms aligned to their respective reference genomes. Numbers to the left of the read
distributions show the highest peak height value in the field as normalized to the total
mapped reads. For gene structure, lines depict introns, boxes depict exons, and thinner
boxes depict UTRs. Genomic distances are shown as dashed black lines.
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Figure 4.11 PCPAed genes and up-regulated genes are proximally grouped in gene
neighborhoods
Genome browser view for the genes PVT1 and MYC genes with 30 minute, 4sU labeled
RNAseq read distributions for control (black) or U1 (red) AMO transfected cells from
human (top) or mouse (bottom) aligned to their respective reference genomes. PVT1 was
identified as PCPAed, and MYC was identified as up-regulated after U1 AMO transfection.
The intergenic distance between then (35kb) is much shorter than that found by randomly
sampling genes (median = 74kb from hg19). Blue box inset shows the zoomed region of
PCPA within the PVT1 gene for both organisms. Numbers to the left of the read
distributions show the highest peak height value in the field as normalized to the total
mapped reads. For gene structure, lines depict introns, boxes depict exons, and thinner
boxes depict UTRs. Genomic distances are shown as dashed black lines.
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Figure 4.12 U1 AMO induced PCPA and down-regulation contributes to proximal
gene up-regulation
Boxplots showing intergenic distance distributions between randomly sampled (red) UPUP (orange), UP-DOWN (green), or UP-PCPA (blue) gene groupings for fly (top-left),
zebrafish (top-right), mouse (bottom-left), or human (bottom-right) genes. Genes were
identified and intergenic distances were calculated as described in the text. Distribution
differences between the all randomly sampled and other three gene groups were tested
for significance using a Student’s t-test.
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Figure 4.13 Upstream antisense transcription is driven sense gene transcription
levels
Boxplots showing the log2 transcription fold change for U1 versus control AMO transfected
cells from fly (top-left), zebrafish (top-right), mouse (bottom-left), or human (bottom-right).
Sense genes were identified as either all expressed (RPKM ≥ 1; white), unchanged (red),
up-regulated (orange), down-regulated (green), or PCPAed (blue) as described in the text.
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Table 2 Relative quantification data for all RT-qPCR samples
Mean relative quantification values from 30 minute, 4sU labeled RNA for three genes
comparing U1 and control AMO transfected NIH-3T3 (Mouse) and S2 (Fly) cells. Primers
for either the first intron or exon 1 to exon 2 were used to quantitate the PCPA to spliced
mRNA ratio, respectively. Quantification is normalized to the control AMO transfected
intron 1 signal.
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Table 3 Organism RNAseq mapping statistics
Numbers for the fly (dm6), zebrafish (danRer10), and mouse (mm10) read alignment of
RNAseq data using TopHat v2.1.1 (Trapnell, Pachter, and Salzberg 2009). Multi-mapped
reads are defined as those which align to 20 or more locations in the genome; read were
filtered to include only the primary alignment of properly mapped pairs using Samtools
v1.9 (Wysoker et al. 2009).
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Table 4 U1 AMO induced PCPA and up-regulated genes is evolutionarily conserved
Numbers of genes expressed (RPKM ≥ 1) or affected by U1 (PCPAed or up-regulated)
compared to control AMO transfected fly, zebrafish, mouse, and human cells from 30
minute, 4sU labeled RNAseq. The overlap of the fly, zebrafish, and mouse affected genes
were compared for ortholog overlap to human for PCPAed as well as up-regulated
groupings, and statistical significance in the overlap was calculated using a
hypergeometric distribution.
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Table 5 Median gene sizes for expressed, PCPAed, and up-regulated genes
Numbers showing the median gene size for all expressed (RPKM ≥ 1), PCPAed, or notPCPAed and up-regulated gene groups in fly, zebrafish, mouse, and human cells for U1
compared to control AMO transfections from 30 minute, 4sU labeled RNAseq. The
variance and standard deviation across these organisms are also calculated.
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Table 6 Median intergenic distances for various gene groups
Numbers showing the median intergenic distances between randomly sampled, UP-UP,
UP-DOWN, or UP-PCPA gene groupings for fly, zebrafish, mouse, or human genes from
30 minute, 4sU labeled RNAseq after transfection with either control or U1 AMO. Genes
were identified and intergenic distances were calculated as described in the text.
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CHAPTER 5: NOVEL EXON SKIPPING AND READ-THROUGH SPLICING
IS CAUSED BY LOW U1 BASE-PAIRING INHIBITION
Chapter Details
Unpublished. Contributing members: Chie Arai, Eric Babiash, Maura Jones (data
interpretation and discussion).
Multi-Exon Skipping
To this point, much of the discussion of my research has revolved around U1 telescripting
and gene structure as it relates to PCPA. As U1’s importance was first shown by the
discovery of its role in splicing through binding of the 5’ss, it would have been remiss of
me not to take a closer look at how splicing was affected by U1 AMO treatments. There
were many software packages already available with which to study alternative splicing,
though each have some drawbacks. For example, MISO required pre-processed
annotation files of known isoforms and cannot discover novel splice formats, while JUM
and MAJIQ were computationally intensive and only analyze specific splicing event types
(Katz et al. 2010; Q. Wang and Rio 2018; Vaquero-Garcia et al. 2016). I decided to analyze
splicing changes observed in our samples from the simpler starting point of using the de
novo splice junctions from the alignment and knock exon-intron boundaries. From this
analysis, I could then easily explore additional avenues of research such as a deeper
examination of specific mis-splicing events.
To begin this analysis, I calculated the overall splicing, as well as splice junctions that map
to all known, annotated splice sites and those that do not. Overall splicing levels
decreased with U1 AMO in almost every human, mouse, zebrafish, and fly RNAseq
sample, with the exception of 5nmol U1 AMO in mouse and 1nmol U1 AMO in fly (Figure
5.1a). As discussed previously in terms of PCPA, the fly cells were less affected overall
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by U1 base pairing inhibition. With this in mind, the minimal changes in splicing are not
out of place when considering the fewer PCPA events and expression changes in the fly
sample. However, the increased splicing in mouse with 5nmol U1 AMO was surprising;
especially given that an expected decrease was seen with the 1nmol U1 AMO treatment.
Closer examination of these junctions in the mouse sample showed that they resulted
from the extremely high up-regulation found in small (median size 6.9kb) genes, for
example Myc, Fos, or Gadd45a.
Despite U1’s requirements for exon definition, U1 AMO only produced minor increases in
non-annotated compared to annotated splice junctions when analyzed globally in mouse
and human samples (Figure 5.1b). In the fly and zebrafish, however, U1 AMO did reduce
overall splicing fidelity considerably. I should note that both of these organisms had high
baseline levels of non-annotated splice junctions, which appear to result from two different
contributing sources. Since I calculated splicing fidelity from previously known and
annotated exon-exon junctions, which are in turn annotated using combinations of
experimental data and sequence-based inferences, the decreased fidelity in zebrafish is
most likely due to the paucity of scientific knowledge about their genes and gene
structures relative to mouse or human. In fly, which is one of the most well-studied
organisms genetically, I found that many of the non-annotated splice junctions came from
high copy number genes, ribosomal RNAs that were not fully depleted from the sample
during cleaning, or non-coding RNAs that are in close proximity in the genome. These
were most likely the result of sequencing and/or alignment error where similar sequences
were called upon to align to nearby genes rather than splicing within a single gene. When
added together, these type of splice junctions accounted for 23-37% of the total nonannotated splicing found in fly, compared to <10% for mouse and 13-40% for zebrafish.
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Thus, U1 base pairing inhibition does reduce overall splicing fidelity in all the organisms
studied; however, the effect was less dramatic than I had initially anticipated.
When visualizing the junctions in all samples using the UCSC Genome Browser, I noticed
the loss of splicing in many genes, especially from PCPA, down-regulation, and decreased
splicing. As reported here, there were also a specific subset of genes where splicing was
unaffected or even increased with U1 AMO. Visualization revealed that inhibiting U1 base
pairing created many instances (between 11-4,341 genes across all organisms) of splicing
that occurred across multiple exons which did not associate to known splice isoforms
(Figure 5.2; full list of genes found in Supplementary Table 2). Additionally, there were
rare, aberrant splicing events observed, where splice junctions occurred within introns,
between introns and exons, or in intergenic space. While it was nearly impossible to
distinguish if these were the result of a technical error in sequencing or in alignment, most
of these were <5 reads in depth, usually only a single read, in comparison to the ≥100
read average for all junctions. These low numbers could perhaps be ascribed to a
background error of some type; however, additional factors suggested caution in this
interpretation. Specifically, these multi-exon skipping events utilized annotated 5’ or 3’
splice sites and were present at lower levels and frequency in control conditions, where
they skipped the same exons. Moreover, these non-canonical splicing events incorporated
higher read numbers than could be expected for technical error alone. As such, I decided
to compile these splicing events together as an indicator of mis-splicing due to U1 base
pairing inhibition.
Having seen several promising splicing events, I now wanted to systematically identify
these novel junctions. Given the high sequencing depth in our samples and the fact that
there were already non-annotated splice junctions at a very low read number, I decided to
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begin by filtering out all splicing events that contained less than five reads. This was done
to remove any junction that could be simply a technical error. I then split the splicing events
into those that were from annotated and consecutive exons (annotated), and those that
were not, but which were still spliced from within a single gene. Within these, I defined the
multi-exon skipping junctions as those that spliced directly from known 5’ and 3’ splice
sites. The remaining events then were put into a group consisting of junctions utilizing
novel splice sites (aberrant or other); these were often offset from annotated splice sites
by only a few bases, suggesting that they resulted either from base calling error during
sequencing or were produced from poorly defined 5’ or 3’ splice sites (although a few
spliced within introns or from an exon into an intron). I decided to count both the number
of events for each splicing category, for analyzing breadth, and the number of reads
grouped into each category, for analyzing depth. As U1 AMO affected the overall splicing
levels, it was important that I compare the multi-exon skipping and aberrant splicing levels
to the number of reads in annotated exon-exon junctions. This ensured that any increase
or decrease in the former two would be taken in the context of what splicing was occurring
within the sample as a whole.
I began with the fly, zebrafish, and mouse RNAseq data. With regard to depth, the total
amount of multi-exon skipping increased by 1-2 fold after U1 AMO treatment in all
organisms (Table 7). The breadth of skipping, however, was not as consistent across
organisms as it decreased for the 1nmol doses in mouse and fly then increased again at
5nmol, while the opposite was true for zebrafish. Higher U1 AMO doses were expected to
induce extensive PCPA, which would reduce the number of exons transcribed from the 3’
ends of genes. In contrast, more attenuated PCPA from a lower U1 AMO dose should, in
theory, have allowed for more exon skipping. As a consequence, I examined the splicing
events in mouse and fly for explanations for their reduced skipping and aberrant splicing
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events at 1nmol U1 AMO. Consistent with the results discussed in the previous chapter,
the fly exhibited much more general up-regulation rather than down-regulation at 1nmol
U1 AMO. This increased mRNA output could explain the decreased levels of exon
skipping in comparison to annotated exon-exon junctions. As mentioned above, the 1nmol
U1 AMO mouse data showed an overall decrease in splicing, which may have been due
to lower sequencing levels when compared to the control and 5nmol U1 AMO (69 versus
159 and 175 million mapped reads, respectively). While the lower depth did not heavily
impact general analyses and transcriptome changes, the already lower levels of
expression seen in the mis-splicing events could have meant that a previously low level
splicing change in a deeply sequenced dataset (>100 million reads) would not possess
enough reads to pass a statistical filter if the total sequencing depth was lowered by half.
I decided to also include a HeLa low U1 AMO titration (0.01, 0.05, 0.25, 0.5 and 1nmol)
RNAseq dataset, carried out by a post-doctoral colleague Jung-Min Oh, into this
examination to help determine whether incomplete U1 base pairing inhibition can stimulate
higher levels of mis-splicing in the human system. It is important to note that these low
levels of U1 AMO do not cause severe PCPA, and so allow for the investigation of other
transcriptome changes that would otherwise be masked by widespread transcription
termination. These samples demonstrated a dose dependent increase in the depth of
multi-exon skipping, as well as a sizable increase in the breadth at 1nmol. Surprisingly,
there were a significant number of aberrant splicing events in all HeLa samples as well,
but not a correlative increase in depth at each splicing location. This observation could
have been explained by the fact that these samples were more deeply sequenced than
the fly, zebrafish, and mouse RNAseq, and, thus, contained more statistical power to
identify mis-splicing events. Alternatively, the higher transcriptional output from highly
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active and cancerous HeLa cells could have already contained more alternative splicing
errors at baseline.
At first, it seemed likely that the breadth of multi-exon skipping would depend on the
number of exons in a gene; I reasoned that the more splice sites there were, the more
likely it was for mis-splicing to occur. However, this proved somewhat untrue, as multiexon skipping was only mildly correlated with exon number (Spearman correlation, 0.10.64 over all four organisms tested) and with aberrant splicing (Spearman correlation,
0.13-0.43 over all four organisms tested); this was also the case for the depth of missplicing (Spearman correlation, 0.09-0.54 and 0.11-0.4 over all four organisms tested)
(Table 8). By comparison, the annotated splicing events were highly correlated with exon
number (Spearman correlation, 0.68-0.96), which was to be expected as they provided
more splicing opportunities. There was also no correlation between skipping breadth or
depth, or changes to them after U1 AMO, and gene size (data not shown).
In order to determine a potential rationale for which exons are skipped and which are
included, I decided to examine the 5’ and 3’ splice site sequences. Most splice sites
conform to a series of consensus sequences so that they can both be recognized by U1
and U2 and carry out the transesterification reaction steps in splicing (Mount 2000; Wahl,
Will, and Lührmann 2009; Will and Lührmann 2011). There are multiple portions of
consensus within both the 5’ and 3’ splice site; the most invariant of these are the
dinucleotides both at the 5’ side of the intron, GT spanning the exon-intron boundary, and
at the 3’ side of the intron, AG at the intron terminus. It seemed likely to me that this exon
skipping could be due to weaker 5’ or 3’ splice site sequences, i.e. ones that do not
conform as well to consensus sequences. To examine this, I used two tools: the first was
sequence logos to look for changes in base pair enrichment at the 5’ and 3’ splice sites
116

and the second was maximum entropy modeling (MaxEnt) on these regions to test for
conformity to known splice site sequences (Crooks et al. 2004; Yeo and Burge 2004). I
was only able to accomplish the latter in mouse and human, as there were readily available
trained splice site databases only for these organisms.
For examining the sequence logos over the 5’ and 3’ splice site, I extracted the target
regions in each sample so as to include 9 nucleotides of the intron as well as 3 nucleotides
of the flanking exon. As I split each group by splice site, inclusion or exclusion for skipping,
as well as by sample, I ended up with 60 separate logos. However, logo sequence did not
change significantly when comparing amongst AMO treatments (data not shown). This is
most likely due to the presence of some exon skipping events in the control, albeit at lower
levels than in U1 AMO. Thus, to consolidate the logos into more manageable pieces, I
combined the sequences for all AMO treatments in each species (Figure 5.3). Both the 5’
and 3’ splice sites had very strong dinucleotide invariance in exons that were not skipped
during splicing. By comparison, these same 5’ and 3’ dinucleotides had a small number of
loci (5-15%) with altered sequences in skipped exons in all organisms. While the change
was rather small, this highlights the importance of this specific two base pair consensus
sequence in maintaining inclusion for an exon during transcription.
For a more quantitative analysis, I scored the splice site sequences used in included or
excluded exons against all known splice sites in the genome. Using the MaxEnt scoring
system resulted in lower median scores for the skipped 5’ and 3’ splice sites, as well as a
considerable number of negative score outliers, in comparison to those exons that were
included (Figure 5.4). It is important to note that these type of scoring systems have no
recognized cutoff for determining usage. In this case, the lower values in the skipped
exons indicated less overall conformity to consensus splice site sequences, which could
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reduce overall exon definition by U1 and U2. Additionally, or perhaps alternatively, the
extreme negative scores seen in some outliers could be the underlying reason for
exclusion as they indicate a splice site that may not be identifiable by one of the snRNPs.
Here, a potential explanation is that the associated exon relies heavily on either U1 or U2,
but not both, to initiate its definition before the other is recruited and the process of splicing
begins.
As the difference between splice site sequences for included and excluded exons within
samples was greater than the sequences across samples, this suggests that multi-exon
skipping is present at low levels in normal cells. The baseline level of exon skipping is
likely from pol II not slowing or pausing long enough at exons, a process known to play a
role in cassette exon inclusion or exclusion (Carrillo Oesterreich, Bieberstein, and
Neugebauer 2011; Oesterreich et al. 2016). In this scenario, splice site sequences that
conform less to the overall consensus may require more time for definition when recruiting
U1 or U2. Another possible explanation to the presence of baseline multi-exon skipping
lies in the branch point sequence, where U2 binds. Any disruption here, similar to a loss
of U1 binding, would reduce exon definition and promote exon exclusion. The position of
this site upstream of the 3’ss, however, can vary by as much as a few hundred nucleotides,
making it difficult to map precisely. I am in the process of scanning for this sequence in
the included or skipped exons detected from my analysis. Despite the difficulty, this is a
promising opportunity, and should be explored further.
Read Through Transcription and Splicing
During visualization of the data on the UCSC Genome Browser, I noticed between a few
instances of read-through transcription between neighboring, same strand genes (Figure
5.5; between 7-154 genes across all organisms, full list of genes found in Supplementary
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Table 3). Importantly, many of these cases also included splicing from one gene into
another, where the intergenic space becomes part of a novel intron between exon skipping
as described above. Transcription between these conjoined genes would then, most likely,
end at the canonical 3’ end of the downstream gene, although U1 AMO treatments could
induce transcription termination within the downstream gene rather than at the canonical
terminus. Read through transcription has been described previously, and as many as 800
conjoined genes have been identified, mainly through computational methods and then
validated experimentally (Akiva et al. 2006; Prakash et al. 2010; Kim et al. 2012). The
novel conjoined transcripts could then produce chimera proteins, potentially increasing
protein complexity within the genome (Thomson et al. 2000). Open reading frame
prediction for these chimeras, however, suggested that the majority of them produce nonfunctional proteins, as only 16% utilized conserved reading frames (Prakash et al. 2010).
I extracted all the read through splicing events from the same samples that I used in my
multi-exon skipping examinations: my U1 AMO treatments in fruit fly, zebrafish, mouse
together with the low U1 AMO dose response from Jung-Min Oh. Also, similar to the multiexon skipping analysis, the changes in levels of read through splicing must take into
consideration the changes in annotated exon-exon junction splicing. In order to make this
comparison, I averaged the splicing from the flanking genes across which the read through
was occurring. In comparison to the control, U1 AMO increased the overall levels of read
through splicing in almost all samples, with the exception of the lose dose (1nmol) in
mouse and the very low dose (0.01nmol) in human (Table 9). When comparing the
distribution of the read through events, however, not all samples were significantly
increased in comparison to the control (Figure 5.6). This is most likely because the overall
read numbers in human are skewed by a few outliers that increase in depth after U1 AMO.
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As I was interested in what could cause the read through splicing, I looked for correlation
between the depth at each site compared to the intergenic distance between the flanking
genes, as well as their splicing depth and expression. None of these, however,
demonstrated any significant correlation (data not shown). Instead, I examined the events
and flanking genes visually to both verify the read through and manually discover potential
cases of interest. There was at least one instance where the flanking genes were
noteworthy due to correlations to disease; in particular, read through between UBE2D3
and MANBA that can be seen with 1nmol U1 AMO in HeLa (Figure 5.5).
UBE2D3 encodes a protein that is a part of an enzymatic family which acts to conjugate
ubiquitin to specific target proteins, which in turn causes the degradation of the target by
the proteasome (Jensen et al. 1995). The E2 family of ubiquitin ligases, in particular,
prevents the accumulation of the tumor suppressor p53 in unstressed cells (Saville et al.
2004). Regulation of p53 has been heavily studied and is believed to serve many roles in
cells; one of the most well-known of these is that upregulation of the protein in response
to stress induces apoptosis in order to prevent the survival of potentially malignant cells
(Ryan, Phillips, and Vousden 2001). p53’s proper function is critical for protecting against
cancer development. The second gene in this read through transcription event, MANBA,
encodes the β-mannosidase enzyme that functions in the lysosome to degrade
disaccharides. Mutations in this gene cause β-mannosidosis, a lysosomal storage disease
that affects neurological development but is rare in humans (Alkhayat, Kraemer, and
Leipprandt 1998; Blomqvist et al. 2019). In addition, polymorphic CA repeats in MANBA
have also recently been linked to colorectal cancer in Swedish patients (Gao et al. 2008).
Due to the very recent discovery of these read through splicing events, this research, even
in its infancy, provides an exciting new area of study for transcription regulation by U1.
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The lower U1 AMO dose where these events occur in the human system are more
physiologically relevant than complete base pairing inhibition that leads to extensive
PCPA. As mentioned previously, low U1 AMO mimics transcriptional changes that are
seen with neuronal activation (Berg et al. 2012). As such, cell stress or stimulation could
also induce read through transcription and splicing between genes such as UBE2D3 and
MANBA. There are several possible explanations for the unresolved elements of
MANBA’s role in neurological development and p53’s many roles including cancer
regulation, if the chimera protein of UBE2D3:β-mannosidase turns out to be stable in vivo.
For example, it could act outside of normal regulatory pathways to repress p53 in the early
stages of malignancy, or it could potentially form toxic aggregates. Further studies could
determine whether this fusion is produced in certain cancer cell or patient populations, as
well as whether the chimera protein is stable and functional.
Overall, this is an interesting result which has potentially important implications; current
research into read through splicing is ongoing by several of my laboratory colleagues.
While we have not done much analysis into these events, it is curious as to why U1
inhibition increases these numbers as a reduction in telescripting, from less free U1,
should induce shorter transcripts. A potential theory for this is that mild U1 inhibition, which
is also critical in defining the terminal exon, causes polymerases to transcribe past the last
3’ss without pausing for splicing. Much more can be done experimentally and analytically
for these events. My work above highlighted only one of 80-120 read through splicing
events found in human; as a consequence, it is possible that there are additional clinically
relevant or scientifically compelling examples to study. I hope to help continue this work
going forward.

121

122

Figure 5.1 U1 AMO reduces overall splicing and splicing fidelity
(a) Stacked bar graphs showing total de novo spliced read numbers, identified by TopHat
v2.1.1 (Trapnell, Pachter, and Salzberg 2009), normalized to the total mapped read
number for control or U1 AMO transfected fly, zebrafish, mouse, or human cells. Spliced
reads are grouped by those that align to consecutive, annotated 5’ and 3’ splice sites
(Previously Annotated, blue) and those that do not (Not Annotated, red). (b) Stacked bar
graphs showing the same data as in a, but scaled to be a representation of splice junction
type by total percent.
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Figure 5.2 U1 AMO increases multi-exon skipping in human and mouse
Genome browser view of the PTMA gene with 30 minute, 4sU labeled RNAseq reads and
spliced junctions spanning multiple exons from control (black) and U1 (red) AMO treated
NIH-3T3 (Mouse) and HeLa (Human) cells. Blue lines with vertical end-brackets show the
splicing location of multi-exon skipping junctions. Numbers to the left of the read
distributions and splice junctions show the highest peak height value in the field and
spliced reads, respectively, as normalized to the total mapped reads. For gene structure,
lines depict introns, boxes depict exons, and thinner boxes depict UTRs. Genomic
distances are shown as dashed black lines.
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Figure 5.3 Skipped exons contain less invariance at the critical dinucleotides at the
5’ and 3’ splice sites
Nine nucleotide splice site logos for the 5’ and 3’ splice sites for fly, zebrafish, mouse, and
human organisms. Taller nucleotide letters indicate higher prevalence of that base at the
position. Splice sites are grouped by those that flank exons which are always included in
previously annotated splice isoforms (Included), and those that are excluded from a novel
multi-exon skipping event (Skipped) as identified in the text from 30 minute, 4sU labeled
and U1 AMO transfected RNAseq datasets. Sequences contain three nucleotides of the
exon and six nucleotides of the intron as bracketed above the logos. The invariant
dinucleotides are bracketed below the logos.
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Figure 5.4 Skipped exons have lower splice site consensus sequence
Boxplots showing the maximum entropy score for 5’ and 3’ splice site sequences in mouse
and human for exons that are either skipped or included in multi-exon skipping events as
identified in the text from 30 minute, 4sU labeled and U1 AMO transfected RNAseq
datasets. Splice site consensus strength was measured using MaxEntScan (Yeo and
Burge 2004). Red dashed line indicates the mean maximum entropy score (8.8) of the
included 5’ and 3’ splice site scores. Values above zero represent scores closer to the
consensus splice site sequences, negative values represent less consensus sequences.
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Figure 5.5 Low U1 AMO read through transcription and splicing
Genome browser view of the genes UBE2D3 and MANBA with 30 minute, 4sU labeled
RNAseq reads and read through spliced junctions from control (black) and U1 (red) AMO
treated and HeLa cells. Blue lines with vertical end-brackets show the splicing location of
read through splice junctions from the low U1 AMO condition. Numbers to the left of the
read distributions and splice junctions show the highest peak height value in the field and
spliced reads, respectively, as normalized to the total mapped reads. For gene structure,
lines depict introns, boxes depict exons, and thinner boxes depict UTRs. Genomic
distances are shown as dashed black lines.
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Figure 5.6 Low U1 AMO increases read through transcription
Boxplots showing the distribution of reads that splice between two adjacent, same strand
transcripts for 30 minute, 4sU labeled RNAseq data of fly, zebrafish, mouse, and human
cells transfected with either control or U1 AMO. Read values were normalized to the total
mapped reads in each sample. Distribution differences between the control and U1 AMO
transfected samples were tested for significance using a Wilcoxon signed-rank test.
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Table 7 U1 AMO increases both multi-exon and other splicing events
(a) Numbers showing the splice junction reads from 30 minute, 4sU labeled RNAseq of
fly, zebrafish, mouse, and human cells transfected with either control (black) or U1 (red)
AMO. Also shown is the percentage of reads in each group as a fraction of the total spliced
reads. (b) Same as in a, except showing the total splicing events (i.e. breadth).
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Table 8 Mis-splicing does not correlate with exon number
Numbers showing the Spearman correlation of splicing events and splicing reads to exon
number as broken down by splice junction type. Shown is the 30 minute, 4sU labeled
RNAseq data for fly, zebrafish, mouse, and human cells transfected with either control
(black) or U1 (red) AMO.
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Table 9 U1 AMO increases the amount of read through splicing
Numbers showing the number of read through splicing events and reads for 30 minute,
4sU labeled RNAseq data fly, zebrafish, mouse, and human cells transfected with either
control (black) or U1 (red) AMO. Also shown is the average number of annotated splice
junction reads from the flanking (upstream and downstream) genes between the read
through events as well as the read through splicing as a percentage of this flanking gene
splicing.

139

CHAPTER 6: IMPACT OF THIS WORK AND FUTURE DIRECTIONS
U1 Telescripting Has Shaped Gene Structure Evolution
When I began work in the Dreyfuss lab, the most recent publications from the group had
demonstrated the existence of U1 telescripting, a function separate to its role in splicing
(Kaida et al. 2010; Berg et al. 2012). This discovery challenged the commonly-held belief
in the RNA processing and transcription fields, that pol II processivity is extremely robust.
Before this, the existing theory regarding transcription was that complete elongation
through the entire length of a transcript is inexorable once the polymerase was engaged
past the promoter. Our lab’s research into U1 telescripting has demonstrated that this is
not true, and that full-length transcription is not the default state in metazoans. The
genomic tiling array and HIDE-seq experiments conducted in our lab leading to these
discoveries were soon replaced with larger and more general RNAseq experiments. As I
highlighted earlier in this work, the novelty of telescripting meant that there were no
available tools or methods to identify or study PCPA or transcription shortening. As a
consequence, I created the tools necessary for the analysis of telescripting from RNAseq
datasets. I combined this computational work with biological experiments to examine the
mechanism of PCPA and the conservation of U1 telescripting in different organisms.
My pol II ChIPseq experiments demonstrated that loss of telescripting, achieved through
U1 AMO but also possible due to transcription up-regulation, caused PCPA through
transcription termination at actionable PASs within large introns of genes (Oh et al. 2017).
This observation was critical to the understanding of telescripting as a co-transcriptional
process, rather than from a post-transcriptional degradation of 3’ side pre-mRNA.
Importantly, this also showed that transcription initiation was not inhibited by U1 AMO, but

140

was increased slightly in PCPAed genes. We postulate that this is most likely due to
increased polymerase recycling from prematurely terminated transcripts in the same gene.
My analytical work, calculating the important parameters in PCPAed genes from RNAseq
data, allowed for the identification of U1 AMO induced transcription termination. This also
revealed the stratification in gene size between PCPAed genes and up-regulated genes
with U1 base pairing inhibition. Moreover, the difference in functional enrichment across
these different gene size groups is an important piece of evidence that helps in our
understanding of how U1 telescripting acted as one potential cause behind gene size
expansion. Using orthology data and U1 AMO RNAseq in fly, mouse, and zebrafish, I have
demonstrated that large transcripts, which typically contain more neuronal and
developmental genes, experienced the most extreme intron expansion (Bertagnolli et al.
2013; Gabel et al. 2015). These larger introns also increase the likelihood of an actionable
PAS arising stochastically, making these transcripts more susceptible to PCPA.
The up-regulation of small genes with U1 AMO was a surprising result, and was consistent
across the organisms I studied. The genes, highly enriched for cell stimuli response or
growth functions, continued to splice and produce full-length mRNA even with virtually no
free U1 present in these cells. Existing possible explanations for this result included, for
example, that U1 AMO transfections could produce a stress response, or that specific
down-regulated genes could be transcription inhibitors. However, my analysis of hnRNP
binding after inducing PCPA suggests an alternative mechanism, one where large genes
are sacrificed in order to provide critical pre-mRNA processing resources to smaller, more
acute cell response genes. Further evidence for this was found in my organism RNAseq,
which showed that these two functionally disparate gene groups are also found in close
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proximity across evolution. This shorter intergenic distance would make the transfer of
these resources much quicker and more reliable.
While there has been research into the evolution of gene size and the purpose of large
introns, our work provides a new and sharply different perspective (Bradnam and Korf
2008; Catania and Lynch 2008; Chorev and Carmel 2012; Gelfman et al. 2012; Rogozin
et al. 2012). Centered around U1 telescripting, intron size expansion has been allowed,
or even promoted, by genome evolution in non-critical “luxury” genes, rather than
occurring randomly and tolerated by metazoan cells. Evolutionary pressure to maintain
the size of small genes while allowing intron expansion in large genes is also supported
by the data that intron length and splice site strength have been shown to be inversely
linked (Gelfman et al. 2012). Introns flanked by weak 5’ss are shorter than average, while
longer introns are found in closer proximity to stronger 5’ss. This purifying selection
against intron expansion near weak splice sites could be explained by the necessity for
stronger U1 interactions in order to prevent PCPA from occurring during the common life
cycle of a cell. The enrichment for cell proliferation and glucose response in small genes
further supports this idea.
The identification of PCPA and the stratified size-function genome has formed a
foundation for a new approach to study transcription and the RNA processing machinery.
One of the most pressing questions is the mechanism of PCPA itself. Though our data
has shown that the transcripts are cleaved and polyadenylated, which suggest a process
at least similar to that found at canonical 3’ gene ends, the actual mechanism of action
remains unknown. Understanding which factors are directly involved at PCPA sites,
through XLIPseq or other cross-linking experiments (CLIPseq or PAR-CLIP) with U1 AMO,
would be a good first step towards elucidating this mechanism. While there has recently
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been confirmation that U1 binds throughout introns, a study of the change in locations with
U1 AMO or cell stimulation could help determine the change in binding that elicits PCPA
(Engreitz et al. 2014). This could also be achieved with XLIP or CLIPseq with antibodies
for U1 specific proteins such as U170K, U1A, or U1C.
On the matter of up-regulation with U1 AMO in small genes, it is important to understand
how these maintain mRNA output when U1 cannot base pair to the 5’ss. While U1 protein
XLIP/CLIP as mentioned above would help for further studies, mass spectrometry and
XLIPseq of other spliceosomal proteins would provide an alternative method to test this.
If, for example, U1 was not base pairing to the 5’ss in these genes, pull downs of U2
specific proteins (ex. U2A’, U2B”, SF3A1, or SF3B1) or exon junction complex proteins
(ex. PRP8, RNPS1, or Y14) could show the composition of the spliceosome at different
stages on these introns.
More narrow identification of the PCPA site, perhaps even down to the level of base pair
specificity, has been a long-time goal in the lab. However, current RNAseq data may not
be sufficiently informative to identify many PCPA sites, from immediate transcript
termination to multiple less active sites across an intron, with acceptable accuracy due to
the varied types of PCPA as seen manually on a genome browser. Despite this, other
mathematical and statistical approaches could be applied to these data in an attempt for
more precise PCPA site determination. For example, there are software packages
available which identify 3’UTR shortening that could be adapted to examine introns or the
entire gene (W. Wang, Wei, and Li 2014; Xia et al. 2014). Another analytical method that
might prove useful would be to use 3’-end sequencing, which is typically accomplished
through oligo-dT primers to target poly(A) sequences mRNA ends (de Hoon and
Hayashizaki 2008; Beck et al. 2010; Shepard et al. 2011). A potential drawback of this
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method is that the oligo-dT can potentially also prime to genomic poly(A) sequences within
a gene and cause false positives during the analytical process. These specific types of
sequencing experiments also limit the amount of data that is able to be used in
downstream work, although this can be offset by doing total RNA sequencing in
conjunction.
Deeper Implications for U1’s Role in Exon Definition
Substantial research has been done investigating both mis-splicing, especially in regards
to disease, and conjoined genes; yet the identification of new read through transcription
sites and splicing events is still an important area in need of further research. My analytical
work on multi-exon skipping provides a fast alternative to discovering novel splicing events
at the gene level. While my workflow is simpler and more specific than other splicing
programs available, its simplicity does not detract from its ability to detect novel splicing
events. The exon skipping I discovered with U1 AMO transfected RNAseq data, highlights
the importance of invariance at the critical dinucleotide splice site sequence. Reporter
constructs using these lower consensus splice sites would help verify the presence of
multi-exon skipping. From an analytical perspective, globally identifying the U2 binding
sites in order to compare this sequence in skipped versus included exons could further
shed light on the mis-splicing. Additionally, analyzing sequencing experiments from U2 or
other spliceosomal protein knock downs may induce more of these skipping events, and
allow for identification of any that were missed in our datasets, with the potential to build
on our current understanding.
An unexpected result from my RNAseq work and analysis was the identification of novel
read through transcription and splicing. Although this very recent result was not the main
focus of my work, this discovery has created many research opportunities for the lab going
144

forward. Going forward, the laboratory should work to identify events that are currently not
in any conjoined gene databases and examine them for significance. For example, one
could consider whether the flanking genes are known to be associated with any disease
states. From there, the chimera protein product can be assessed from sequence data and
examined for function, cellular localization, stability, and any other pertinent criteria.
Localization and stability studies can be accomplished through the creation of an antibody
targeted to the fusion region of the two proteins. In the case of disease association, a more
advanced study could express the chimera protein in an animal model, such as zebrafish
or mouse, to search for chimeric protein accumulation.
Final Remarks
This thesis presents a series of experimental and analytical examinations that
demonstrate the importance of U1 telescripting. The consequence of a transcriptional
regulator that links gene size and function is significant, and this is, to my knowledge, the
first evidence that these two gene features are connected. U1’s function in splicing has
been extensively researched, but this has proven to be only the tip of the iceberg with
regards to its function in transcription regulation. There is a certain elegance in what we
now know to be nature’s utilization of U1: its 5’ sequence of 9-nucleotides is necessary for
transcription to continue far enough within a gene so that the same sequence can then be
used for splicing (Venters et al. 2019). It is not clear, however, which of these functions
came first in evolution. Perhaps further work will identify U1’s origin and initial function; it
may also identify even more mechanisms or processes regulated by this small
ribonucleoprotein.
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APPENDIX
Code deposition

Code for the projects listed in the Methods section can be found on GitHub
(https://github.com/ChrisVenters/DreyfussLab) with the following sub-directories:
1. PCPA detection software:
https://github.com/ChrisVenters/DreyfussLab/tree/master/PCPA_detection
2. Ortholog extraction and overlap:
https://github.com/ChrisVenters/DreyfussLab/tree/master/Ortholog_data
3. Multi-exon skipping and mis-splicing identification:
https://github.com/ChrisVenters/DreyfussLab/tree/master/MultiExon_skipping
4. Read through splicing identification:
https://github.com/ChrisVenters/DreyfussLab/tree/master/Read_through_splicing
5. Gene neighborhoods/intergenic distance calculations:
https://github.com/ChrisVenters/DreyfussLab/tree/master/Gene_neighborhoods
6. Upstream antisense region creation:
https://github.com/ChrisVenters/DreyfussLab/tree/master/Upstream_antisense_r
egions
7. snRNA alignments for XLIPseq:
https://github.com/ChrisVenters/DreyfussLab/tree/master/snRNA_alignment

PCR primers
Mouse CRIM1 Exon 1 – Exon 2 Junction, Forward:
CTCCATCACCGAGTACGAAGTG
Mouse CRIM1 Exon 1 – Exon 2 Junction, Reverse:
GGTTTTCATTGCAGGGTTCAA
Mouse CRIM1 Intron 1, Forward:
CGGGCGCGGAACAAA
Mouse CRIM1 Intron 1, Reverse:
CCCCGGGAACCCTCTCT
Mouse GLUD1 Exon 1 – Exon 2 Junction, Forward:
GCAAGGGAGGTATCCGTTACAG
Mouse GLUD1 Exon 1 – Exon 2 Junction, Reverse:
TCATTAAGGAAGCCAGTGCTTTT
Mouse GLUD1 Intron 1, Forward:
GCCTCGGTGCCTGTCATG
Mouse GLUD1 Intron 1, Reverse
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GTCGGCTGCTGGCGTTA
Mouse MYO10 Exon 1, Forward:
GGAGCACTTCGCCCAGAA
Mouse MYO10 Exon 1, Reverse:
CCCAACCACAGCCTTTGTCT
Mouse MYO10 Exon 2, Forward:
CGGGTCTGGCTAAGAGAAAATG
Mouse MYO10 Exon 2, Reverse:
GCCTTCTGCACAGGAATTTACA
Mouse MYO10 Intron 1, Forward:
GCCGGCCCCGAGTCT
Mouse MYO10 Intron 1, Reverse:
TGCGAGCGCAGGACAAA
Fly NIPPEDA Exon 1 – Exon 2 Junction, Forward:
AAATACAATGCAACACATACGTAAACTG
Fly NIPPEDA Exon 1 – Exon 2 Junction, Reverse:
TTGTCTTTACATGTTGCCTTAAGCTT
Fly NIPPEDA Intron 1, Forward:
TTCGGTGCCCTAGTAACAATCTTT
Fly NIPPEDA Intron 1, Reverse:
CACAATGCACGGTCGTTTTAA
Fly SPEN Exon 1, Forward:
CGCGCGTCGTTTGCA
Fly SPEN Exon 1, Reverse:
GCTCGCCGCCGTTGT
Fly SPEN Exon 2, Forward:
GGAGGGCGCCCATTTAAA
Fly SPEN Exon 2, Reverse:
GGAGCATTGCGTCGTATGC
Fly SPEN Intron 1, Forward:
CGCAAATGGTAAGAATGGATCA
Fly SPEN Intron 1, Reverse:
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TTTCCGTGAATGGATTATTTGCT
Fly TENM Exon 1, Forward:
CGCACGGTCGGAATTGTC
Fly TENM Exon 1, Reverse:
CGCTGTTTTCGCTACTTTTCG
Fly TENM Exon 2, Forward:
CGGCACCACCGGATGTT
Fly TENM Exon 1, Reverse:
CCATTTTGCATGCGACTCAT
Fly TENM Intron 1, Forward:
GCAGTGTGGTCAGTGGAATCA
Fly TENM Intron 1, Reverse:
CGCTCTATTTGGGCCACTAAA
Human AFM Promoter, Forward:
TGTGCATACTTAGCCTGTGGACTT
Human AFM Promoter, Reverse:
TTACCTTTGTGTTTCGCTGGAA
Human GAPDH Promoter, Forward:
GGTGCGTGCCCAGTTGA
Human GAPDH Promoter, Reverse:
CTACTTTCTCCCCGCTTTTTTTT
Human GAPDH Exon 1, Forward:
CCTCCCGCTTCGCTCTCT
Human GAPDH Exon 1, Reverse:
GGCGACGCAAAAGAAGATG
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